[
    {
        "page_number": 1,
        "section_number": 1,
        "content": "HIGHLIGHTS OF PRESCRIBING INFORMATION",
        "metadata": {
            "section_title": "HIGHLIGHTS OF PRESCRIBING INFORMATION"
        }
    },
    {
        "page_number": 1,
        "section_number": 2,
        "content": "These highlights do not include all the information needed to use",
        "metadata": {
            "section_title": "These highlights do not include all the information needed to use"
        }
    },
    {
        "page_number": 1,
        "section_number": 3,
        "content": "Azithromycin safely and effectively. See full prescribing information for",
        "metadata": {
            "section_title": "Azithromycin safely and effectively. See full prescribing information for"
        }
    },
    {
        "page_number": 1,
        "section_number": 4,
        "content": "Azithromycin.",
        "metadata": {
            "section_title": "Azithromycin."
        }
    },
    {
        "page_number": 1,
        "section_number": 5,
        "content": "AZITHROMYCIN for injection, for intravenous use",
        "metadata": {
            "section_title": "AZITHROMYCIN for injection, for intravenous use"
        }
    },
    {
        "page_number": 1,
        "section_number": 6,
        "content": "Initial U.S. Approval: 2009",
        "metadata": {
            "section_title": "Initial U.S. Approval: 2009"
        }
    },
    {
        "page_number": 1,
        "section_number": 7,
        "content": "RECENT MAJOR CHANGES",
        "metadata": {
            "section_title": "RECENT MAJOR CHANGES"
        }
    },
    {
        "page_number": 1,
        "section_number": 8,
        "content": "Warnings and Precautions, Cardiovascular Death (5.5) 11/2021",
        "metadata": {
            "section_title": "Warnings and Precautions, Cardiovascular Death (5.5) 11/2021"
        }
    },
    {
        "page_number": 1,
        "section_number": 9,
        "content": "INDICATIONS AND USAGE",
        "metadata": {
            "section_title": "INDICATIONS AND USAGE"
        }
    },
    {
        "page_number": 1,
        "section_number": 10,
        "content": "Azithromycin is a macrolide antibacterial drug indicated for mild to",
        "metadata": {
            "section_title": "Azithromycin is a macrolide antibacterial drug indicated for mild to"
        }
    },
    {
        "page_number": 1,
        "section_number": 11,
        "content": "moderate infections caused by designated, susceptible bacteria:",
        "metadata": {
            "section_title": "moderate infections caused by designated, susceptible bacteria:"
        }
    },
    {
        "page_number": 1,
        "section_number": 12,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 13,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 14,
        "content": "To reduce the development of drug-resistant bacteria and maintain the",
        "metadata": {
            "section_title": "To reduce the development of drug-resistant bacteria and maintain the"
        }
    },
    {
        "page_number": 1,
        "section_number": 15,
        "content": "effectiveness of azithromycin and other antibacterial drugs, azithromycin",
        "metadata": {
            "section_title": "effectiveness of azithromycin and other antibacterial drugs, azithromycin"
        }
    },
    {
        "page_number": 1,
        "section_number": 16,
        "content": "should be used only to treat or prevent infections that are proven or strongly",
        "metadata": {
            "section_title": "should be used only to treat or prevent infections that are proven or strongly"
        }
    },
    {
        "page_number": 1,
        "section_number": 17,
        "content": "suspected to be caused by susceptible bacteria. (1.3)",
        "metadata": {
            "section_title": "suspected to be caused by susceptible bacteria. (1.3)"
        }
    },
    {
        "page_number": 1,
        "section_number": 18,
        "content": "DOSAGE AND ADMINISTRATION",
        "metadata": {
            "section_title": "DOSAGE AND ADMINISTRATION"
        }
    },
    {
        "page_number": 1,
        "section_number": 19,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 20,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 21,
        "content": "DOSAGE FORMS AND STRENGTHS",
        "metadata": {
            "section_title": "DOSAGE FORMS AND STRENGTHS"
        }
    },
    {
        "page_number": 1,
        "section_number": 22,
        "content": "Azithromycin for Injection is supplied as white to off-white lyophilized",
        "metadata": {
            "section_title": "Azithromycin for Injection is supplied as white to off-white lyophilized"
        }
    },
    {
        "page_number": 1,
        "section_number": 23,
        "content": "powder in a single-dose vial equivalent to 500 mg of azithromycin for",
        "metadata": {
            "section_title": "powder in a single-dose vial equivalent to 500 mg of azithromycin for"
        }
    },
    {
        "page_number": 1,
        "section_number": 24,
        "content": "intravenous administration. (3)",
        "metadata": {
            "section_title": "intravenous administration. (3)"
        }
    },
    {
        "page_number": 1,
        "section_number": 25,
        "content": "CONTRAINDICATIONS",
        "metadata": {
            "section_title": "CONTRAINDICATIONS"
        }
    },
    {
        "page_number": 1,
        "section_number": 26,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 27,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 1,
        "section_number": 28,
        "content": "WARNINGS AND PRECAUTIONS",
        "metadata": {
            "section_title": "WARNINGS AND PRECAUTIONS"
        }
    },
    {
        "page_number": 1,
        "section_number": 29,
        "content": "Serious (including fatal) allergic and skin reactions. Discontinue",
        "metadata": {
            "section_title": "Serious (including fatal) allergic and skin reactions. Discontinue"
        }
    },
    {
        "page_number": 1,
        "section_number": 30,
        "content": "azithromycin and initiate appropriate therapy if reaction occurs. (5.1)",
        "metadata": {
            "section_title": "azithromycin and initiate appropriate therapy if reaction occurs. (5.1)"
        }
    },
    {
        "page_number": 1,
        "section_number": 31,
        "content": "Hepatotoxicity: Severe and sometimes fatal, hepatoxicity has been",
        "metadata": {
            "section_title": "Hepatotoxicity: Severe and sometimes fatal, hepatoxicity has been"
        }
    },
    {
        "page_number": 1,
        "section_number": 32,
        "content": "reported. Discontinue azithromycin immediately if signs and symptoms",
        "metadata": {
            "section_title": "reported. Discontinue azithromycin immediately if signs and symptoms"
        }
    },
    {
        "page_number": 1,
        "section_number": 33,
        "content": "of hepatitis occur. (5.2)",
        "metadata": {
            "section_title": "of hepatitis occur. (5.2)"
        }
    },
    {
        "page_number": 1,
        "section_number": 34,
        "content": "Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of",
        "metadata": {
            "section_title": "Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of"
        }
    },
    {
        "page_number": 1,
        "section_number": 35,
        "content": "azithromycin in neonates (treatment up to 42 days of life), IHPS has been",
        "metadata": {
            "section_title": "azithromycin in neonates (treatment up to 42 days of life), IHPS has been"
        }
    },
    {
        "page_number": 1,
        "section_number": 36,
        "content": "reported. Direct parents and caregivers to contact their physician if",
        "metadata": {
            "section_title": "reported. Direct parents and caregivers to contact their physician if"
        }
    },
    {
        "page_number": 1,
        "section_number": 37,
        "content": "vomiting or irritability with feeding occurs. (5.3)",
        "metadata": {
            "section_title": "vomiting or irritability with feeding occurs. (5.3)"
        }
    },
    {
        "page_number": 1,
        "section_number": 38,
        "content": "Prolongation of QT interval and cases of torsades de pointes have been",
        "metadata": {
            "section_title": "Prolongation of QT interval and cases of torsades de pointes have been"
        }
    },
    {
        "page_number": 1,
        "section_number": 39,
        "content": "reported. This risk which can be fatal should be considered in patients",
        "metadata": {
            "section_title": "reported. This risk which can be fatal should be considered in patients"
        }
    },
    {
        "page_number": 1,
        "section_number": 40,
        "content": "with certain cardiovascular disorders including known QT prolongation",
        "metadata": {
            "section_title": "with certain cardiovascular disorders including known QT prolongation"
        }
    },
    {
        "page_number": 1,
        "section_number": 41,
        "content": "or history torsades de pointes, those with proarrhythmic conditions, and",
        "metadata": {
            "section_title": "or history torsades de pointes, those with proarrhythmic conditions, and"
        }
    },
    {
        "page_number": 1,
        "section_number": 42,
        "content": "with other drugs that prolong the QT interval. (5.4)",
        "metadata": {
            "section_title": "with other drugs that prolong the QT interval. (5.4)"
        }
    },
    {
        "page_number": 1,
        "section_number": 43,
        "content": "Cardiovascular Death: Some observational studies have shown an",
        "metadata": {
            "section_title": "Cardiovascular Death: Some observational studies have shown an"
        }
    },
    {
        "page_number": 1,
        "section_number": 44,
        "content": "approximately two-fold increased short-term potential risk of acute",
        "metadata": {
            "section_title": "approximately two-fold increased short-term potential risk of acute"
        }
    },
    {
        "page_number": 1,
        "section_number": 45,
        "content": "cardiovascular death in adults exposed to azithromycin relative to other",
        "metadata": {
            "section_title": "cardiovascular death in adults exposed to azithromycin relative to other"
        }
    },
    {
        "page_number": 1,
        "section_number": 46,
        "content": "antibacterial drugs, including amoxicillin. Consider balancing this",
        "metadata": {
            "section_title": "antibacterial drugs, including amoxicillin. Consider balancing this"
        }
    },
    {
        "page_number": 1,
        "section_number": 47,
        "content": "potential risk with treatment benefits when prescribing azithromycin (5.5)",
        "metadata": {
            "section_title": "potential risk with treatment benefits when prescribing azithromycin (5.5)"
        }
    },
    {
        "page_number": 1,
        "section_number": 48,
        "content": "Clostridioides difficile-Associated Diarrhea: Evaluate patients if diarrhea",
        "metadata": {
            "section_title": "Clostridioides difficile-Associated Diarrhea: Evaluate patients if diarrhea"
        }
    },
    {
        "page_number": 1,
        "section_number": 49,
        "content": "occurs. (5.6)",
        "metadata": {
            "section_title": "occurs. (5.6)"
        }
    },
    {
        "page_number": 1,
        "section_number": 50,
        "content": "Azithromycin may exacerbate muscle weakness in persons with",
        "metadata": {
            "section_title": "Azithromycin may exacerbate muscle weakness in persons with"
        }
    },
    {
        "page_number": 1,
        "section_number": 51,
        "content": "myasthenia gravis. (5.7)",
        "metadata": {
            "section_title": "myasthenia gravis. (5.7)"
        }
    },
    {
        "page_number": 1,
        "section_number": 52,
        "content": "ADVERSEREACTIONSCommunity-acquired pneumonia in adults (1.1)",
        "metadata": {
            "section_title": "ADVERSEREACTIONSCommunity-acquired pneumonia in adults (1.1)"
        }
    },
    {
        "page_number": 1,
        "section_number": 53,
        "content": "Pelvic inflammatory disease (1.2)",
        "metadata": {
            "section_title": "Pelvic inflammatory disease (1.2)"
        }
    },
    {
        "page_number": 1,
        "section_number": 54,
        "content": "Community-acquired pneumonia: 500 mg as a single daily dose by the",
        "metadata": {
            "section_title": "Community-acquired pneumonia: 500 mg as a single daily dose by the"
        }
    },
    {
        "page_number": 1,
        "section_number": 55,
        "content": "intravenous route for at least two days. (2.1)",
        "metadata": {
            "section_title": "intravenous route for at least two days. (2.1)"
        }
    },
    {
        "page_number": 1,
        "section_number": 56,
        "content": "Pelvic inflammatory disease in adults: 500 mg as a single daily dose by",
        "metadata": {
            "section_title": "Pelvic inflammatory disease in adults: 500 mg as a single daily dose by"
        }
    },
    {
        "page_number": 1,
        "section_number": 57,
        "content": "the intravenous route for one or two days. (2.2)",
        "metadata": {
            "section_title": "the intravenous route for one or two days. (2.2)"
        }
    },
    {
        "page_number": 1,
        "section_number": 58,
        "content": "Patients with known hypersensitivity to azithromycin, erythromycin,",
        "metadata": {
            "section_title": "Patients with known hypersensitivity to azithromycin, erythromycin,"
        }
    },
    {
        "page_number": 1,
        "section_number": 59,
        "content": "any macrolide, or ketolide antibacterial drug. (4.1)",
        "metadata": {
            "section_title": "any macrolide, or ketolide antibacterial drug. (4.1)"
        }
    },
    {
        "page_number": 1,
        "section_number": 60,
        "content": "Patients with a history of cholestatic jaundice/hepatic dysfunction",
        "metadata": {
            "section_title": "Patients with a history of cholestatic jaundice/hepatic dysfunction"
        }
    },
    {
        "page_number": 1,
        "section_number": 61,
        "content": "associated with prior use of azithromycin. (4.2)",
        "metadata": {
            "section_title": "associated with prior use of azithromycin. (4.2)"
        }
    },
    {
        "page_number": 2,
        "section_number": 1,
        "content": "ADVERSE REACTIONS",
        "metadata": {
            "section_title": "ADVERSE REACTIONS"
        }
    },
    {
        "page_number": 2,
        "section_number": 2,
        "content": "Most common adverse reactions are nausea (4%), diarrhea (4%), abdominal",
        "metadata": {
            "section_title": "Most common adverse reactions are nausea (4%), diarrhea (4%), abdominal"
        }
    },
    {
        "page_number": 2,
        "section_number": 3,
        "content": "pain (3%), or vomiting (1%). (6)",
        "metadata": {
            "section_title": "pain (3%), or vomiting (1%). (6)"
        }
    },
    {
        "page_number": 2,
        "section_number": 4,
        "content": "To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc.",
        "metadata": {
            "section_title": "To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc."
        }
    },
    {
        "page_number": 2,
        "section_number": 5,
        "content": "at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",
        "metadata": {
            "section_title": "at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
        }
    },
    {
        "page_number": 2,
        "section_number": 6,
        "content": "DRUG INTERACTIONS",
        "metadata": {
            "section_title": "DRUG INTERACTIONS"
        }
    },
    {
        "page_number": 2,
        "section_number": 7,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 2,
        "section_number": 8,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 2,
        "section_number": 9,
        "content": "USE IN SPECIFIC POPULATIONS",
        "metadata": {
            "section_title": "USE IN SPECIFIC POPULATIONS"
        }
    },
    {
        "page_number": 2,
        "section_number": 10,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 2,
        "section_number": 11,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 2,
        "section_number": 12,
        "content": "See 17 for PATIENT COUNSELING INFORMATION.",
        "metadata": {
            "section_title": "See 17 for PATIENT COUNSELING INFORMATION."
        }
    },
    {
        "page_number": 2,
        "section_number": 13,
        "content": "Revised: 2/2022",
        "metadata": {
            "section_title": "Revised: 2/2022"
        }
    },
    {
        "page_number": 2,
        "section_number": 14,
        "content": "FULL  PRESCRIBING INFORMA TION: CONTENTS *",
        "metadata": {
            "section_title": "FULL  PRESCRIBING INFORMA TION: CONTENTS *"
        }
    },
    {
        "page_number": 2,
        "section_number": 15,
        "content": "1 INDICA TIONS AND USAGE",
        "metadata": {
            "section_title": "1 INDICA TIONS AND USAGE"
        }
    },
    {
        "page_number": 2,
        "section_number": 16,
        "content": "1.1 Community-Acquired Pneumonia",
        "metadata": {
            "section_title": "1.1 Community-Acquired Pneumonia"
        }
    },
    {
        "page_number": 2,
        "section_number": 17,
        "content": "1.2 Pelvic Inflammatory Disease",
        "metadata": {
            "section_title": "1.2 Pelvic Inflammatory Disease"
        }
    },
    {
        "page_number": 2,
        "section_number": 18,
        "content": "1.3 Usage",
        "metadata": {
            "section_title": "1.3 Usage"
        }
    },
    {
        "page_number": 2,
        "section_number": 19,
        "content": "2 DOSAGE AND ADMINISTRA TION",
        "metadata": {
            "section_title": "2 DOSAGE AND ADMINISTRA TION"
        }
    },
    {
        "page_number": 2,
        "section_number": 20,
        "content": "2.1 Community-Acquired Pneumonia",
        "metadata": {
            "section_title": "2.1 Community-Acquired Pneumonia"
        }
    },
    {
        "page_number": 2,
        "section_number": 21,
        "content": "2.2 Pelvic Inflammatory Disease",
        "metadata": {
            "section_title": "2.2 Pelvic Inflammatory Disease"
        }
    },
    {
        "page_number": 2,
        "section_number": 22,
        "content": "2.3 Preparation of the Solution for IntravenousNelfinavir: Close monitoring for known adverse reactions of",
        "metadata": {
            "section_title": "2.3 Preparation of the Solution for IntravenousNelfinavir: Close monitoring for known adverse reactions of"
        }
    },
    {
        "page_number": 2,
        "section_number": 23,
        "content": "azithromycin, such as liver enzyme abnormalities and hearing",
        "metadata": {
            "section_title": "azithromycin, such as liver enzyme abnormalities and hearing"
        }
    },
    {
        "page_number": 2,
        "section_number": 24,
        "content": "impairment, is warranted. (7.1)",
        "metadata": {
            "section_title": "impairment, is warranted. (7.1)"
        }
    },
    {
        "page_number": 2,
        "section_number": 25,
        "content": "Warfarin: Use with azithromycin may increase coagulation times;",
        "metadata": {
            "section_title": "Warfarin: Use with azithromycin may increase coagulation times;"
        }
    },
    {
        "page_number": 2,
        "section_number": 26,
        "content": "monitor prothrombin time. (7.2)",
        "metadata": {
            "section_title": "monitor prothrombin time. (7.2)"
        }
    },
    {
        "page_number": 2,
        "section_number": 27,
        "content": "Pediatric use: Safety and effectiveness in the treatment of patients",
        "metadata": {
            "section_title": "Pediatric use: Safety and effectiveness in the treatment of patients"
        }
    },
    {
        "page_number": 2,
        "section_number": 28,
        "content": "under 16 years of age have not been established. (8.4)",
        "metadata": {
            "section_title": "under 16 years of age have not been established. (8.4)"
        }
    },
    {
        "page_number": 2,
        "section_number": 29,
        "content": "Geriatric use: Elderly patients may be more susceptible to development",
        "metadata": {
            "section_title": "Geriatric use: Elderly patients may be more susceptible to development"
        }
    },
    {
        "page_number": 2,
        "section_number": 30,
        "content": "of torsades de pointes arrhythmias. (8.5)",
        "metadata": {
            "section_title": "of torsades de pointes arrhythmias. (8.5)"
        }
    },
    {
        "page_number": 3,
        "section_number": 1,
        "content": "Administration",
        "metadata": {
            "section_title": "Administration"
        }
    },
    {
        "page_number": 3,
        "section_number": 2,
        "content": "3 DOSAGE FORMS AND STRENGTHS",
        "metadata": {
            "section_title": "3 DOSAGE FORMS AND STRENGTHS"
        }
    },
    {
        "page_number": 3,
        "section_number": 3,
        "content": "4 CONTRAINDICA TIONS",
        "metadata": {
            "section_title": "4 CONTRAINDICA TIONS"
        }
    },
    {
        "page_number": 3,
        "section_number": 4,
        "content": "4.1 Hypersensitivity",
        "metadata": {
            "section_title": "4.1 Hypersensitivity"
        }
    },
    {
        "page_number": 3,
        "section_number": 5,
        "content": "4.2 Hepatic Dysfunction",
        "metadata": {
            "section_title": "4.2 Hepatic Dysfunction"
        }
    },
    {
        "page_number": 3,
        "section_number": 6,
        "content": "5 WARNINGS AND PRECAUTIONS",
        "metadata": {
            "section_title": "5 WARNINGS AND PRECAUTIONS"
        }
    },
    {
        "page_number": 3,
        "section_number": 7,
        "content": "5.1 Hypersensitivity",
        "metadata": {
            "section_title": "5.1 Hypersensitivity"
        }
    },
    {
        "page_number": 3,
        "section_number": 8,
        "content": "5.2 Hepatotoxicity",
        "metadata": {
            "section_title": "5.2 Hepatotoxicity"
        }
    },
    {
        "page_number": 3,
        "section_number": 9,
        "content": "5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)",
        "metadata": {
            "section_title": "5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)"
        }
    },
    {
        "page_number": 3,
        "section_number": 10,
        "content": "5.4 QT  Prolongation",
        "metadata": {
            "section_title": "5.4 QT  Prolongation"
        }
    },
    {
        "page_number": 3,
        "section_number": 11,
        "content": "5.5 Cardiovascular Death",
        "metadata": {
            "section_title": "5.5 Cardiovascular Death"
        }
    },
    {
        "page_number": 3,
        "section_number": 12,
        "content": "5.6 Clostridioides difficile -Associated Diarrhea",
        "metadata": {
            "section_title": "5.6 Clostridioides difficile -Associated Diarrhea"
        }
    },
    {
        "page_number": 3,
        "section_number": 13,
        "content": "5.7 Exacerbation of Myasthenia Gravis",
        "metadata": {
            "section_title": "5.7 Exacerbation of Myasthenia Gravis"
        }
    },
    {
        "page_number": 3,
        "section_number": 14,
        "content": "5.8 Infusion Site Reactions",
        "metadata": {
            "section_title": "5.8 Infusion Site Reactions"
        }
    },
    {
        "page_number": 3,
        "section_number": 15,
        "content": "5.9 Development of Drug-Resistant Bacteria",
        "metadata": {
            "section_title": "5.9 Development of Drug-Resistant Bacteria"
        }
    },
    {
        "page_number": 3,
        "section_number": 16,
        "content": "6 ADVERSE REACTIONS",
        "metadata": {
            "section_title": "6 ADVERSE REACTIONS"
        }
    },
    {
        "page_number": 3,
        "section_number": 17,
        "content": "6.1 Clinical Trials Experience",
        "metadata": {
            "section_title": "6.1 Clinical Trials Experience"
        }
    },
    {
        "page_number": 3,
        "section_number": 18,
        "content": "6.2 Postmarketing Experience",
        "metadata": {
            "section_title": "6.2 Postmarketing Experience"
        }
    },
    {
        "page_number": 3,
        "section_number": 19,
        "content": "6.3 Laboratory Abnormalities",
        "metadata": {
            "section_title": "6.3 Laboratory Abnormalities"
        }
    },
    {
        "page_number": 3,
        "section_number": 20,
        "content": "7 DRUG INTERACTIONS",
        "metadata": {
            "section_title": "7 DRUG INTERACTIONS"
        }
    },
    {
        "page_number": 3,
        "section_number": 21,
        "content": "7.1 Nelfinavir",
        "metadata": {
            "section_title": "7.1 Nelfinavir"
        }
    },
    {
        "page_number": 3,
        "section_number": 22,
        "content": "7.2 Warfarin",
        "metadata": {
            "section_title": "7.2 Warfarin"
        }
    },
    {
        "page_number": 3,
        "section_number": 23,
        "content": "7.3 Potential Drug-Drug Interaction with Macrolides",
        "metadata": {
            "section_title": "7.3 Potential Drug-Drug Interaction with Macrolides"
        }
    },
    {
        "page_number": 3,
        "section_number": 24,
        "content": "8 USE IN SPECIFIC POPULA TIONS",
        "metadata": {
            "section_title": "8 USE IN SPECIFIC POPULA TIONS"
        }
    },
    {
        "page_number": 3,
        "section_number": 25,
        "content": "8.1 Pregnancy",
        "metadata": {
            "section_title": "8.1 Pregnancy"
        }
    },
    {
        "page_number": 3,
        "section_number": 26,
        "content": "8.2 Lactation",
        "metadata": {
            "section_title": "8.2 Lactation"
        }
    },
    {
        "page_number": 3,
        "section_number": 27,
        "content": "8.4 Pediatric Use",
        "metadata": {
            "section_title": "8.4 Pediatric Use"
        }
    },
    {
        "page_number": 3,
        "section_number": 28,
        "content": "8.5 Geriatric Use",
        "metadata": {
            "section_title": "8.5 Geriatric Use"
        }
    },
    {
        "page_number": 3,
        "section_number": 29,
        "content": "10 OVERDOSAGE",
        "metadata": {
            "section_title": "10 OVERDOSAGE"
        }
    },
    {
        "page_number": 3,
        "section_number": 30,
        "content": "11 DESCRIPTION",
        "metadata": {
            "section_title": "11 DESCRIPTION"
        }
    },
    {
        "page_number": 3,
        "section_number": 31,
        "content": "12 CLINICAL  PHARMACOLOGY",
        "metadata": {
            "section_title": "12 CLINICAL  PHARMACOLOGY"
        }
    },
    {
        "page_number": 3,
        "section_number": 32,
        "content": "12.1 Mechanism of Action",
        "metadata": {
            "section_title": "12.1 Mechanism of Action"
        }
    },
    {
        "page_number": 3,
        "section_number": 33,
        "content": "12.2 Pharmacodynamics",
        "metadata": {
            "section_title": "12.2 Pharmacodynamics"
        }
    },
    {
        "page_number": 3,
        "section_number": 34,
        "content": "12.3 Pharmacokinetics",
        "metadata": {
            "section_title": "12.3 Pharmacokinetics"
        }
    },
    {
        "page_number": 3,
        "section_number": 35,
        "content": "12.4 Microbiology",
        "metadata": {
            "section_title": "12.4 Microbiology"
        }
    },
    {
        "page_number": 3,
        "section_number": 36,
        "content": "13 NONCLINICAL  TOXICOLOGY",
        "metadata": {
            "section_title": "13 NONCLINICAL  TOXICOLOGY"
        }
    },
    {
        "page_number": 3,
        "section_number": 37,
        "content": "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility",
        "metadata": {
            "section_title": "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility"
        }
    },
    {
        "page_number": 3,
        "section_number": 38,
        "content": "13.2 Animal Toxicology and/or Pharmacology",
        "metadata": {
            "section_title": "13.2 Animal Toxicology and/or Pharmacology"
        }
    },
    {
        "page_number": 3,
        "section_number": 39,
        "content": "14 CLINICAL  STUDIES",
        "metadata": {
            "section_title": "14 CLINICAL  STUDIES"
        }
    },
    {
        "page_number": 3,
        "section_number": 40,
        "content": "14.1 Community-Acquired Pneumonia",
        "metadata": {
            "section_title": "14.1 Community-Acquired Pneumonia"
        }
    },
    {
        "page_number": 3,
        "section_number": 41,
        "content": "16 HOW  SUPPLIED/ST ORAGE AND HANDLING",
        "metadata": {
            "section_title": "16 HOW  SUPPLIED/ST ORAGE AND HANDLING"
        }
    },
    {
        "page_number": 3,
        "section_number": 42,
        "content": "17 PATIENT  COUNSELING INFORMA TION",
        "metadata": {
            "section_title": "17 PATIENT  COUNSELING INFORMA TION"
        }
    },
    {
        "page_number": 3,
        "section_number": 43,
        "content": "*",
        "metadata": {
            "section_title": "*"
        }
    },
    {
        "page_number": 3,
        "section_number": 44,
        "content": "FULL  PRESCRIBING INFORMA TION",
        "metadata": {
            "section_title": "FULL  PRESCRIBING INFORMA TION"
        }
    },
    {
        "page_number": 3,
        "section_number": 45,
        "content": "1 INDICA TIONS AND USAGE",
        "metadata": {
            "section_title": "1 INDICA TIONS AND USAGE"
        }
    },
    {
        "page_number": 3,
        "section_number": 46,
        "content": "Azithromycin for Injection, USP  is a macrolide antibacterial drug indicated for the treatment of patients with infections caused",
        "metadata": {
            "section_title": "Azithromycin for Injection, USP  is a macrolide antibacterial drug indicated for the treatment of patients with infections caused"
        }
    },
    {
        "page_number": 3,
        "section_number": 47,
        "content": "by susceptible strains of the designated microor ganisms in the conditions listed below .",
        "metadata": {
            "section_title": "by susceptible strains of the designated microor ganisms in the conditions listed below ."
        }
    },
    {
        "page_number": 3,
        "section_number": 48,
        "content": "1.1 Community-Acquir ed Pneumonia",
        "metadata": {
            "section_title": "1.1 Community-Acquir ed Pneumonia"
        }
    },
    {
        "page_number": 3,
        "section_number": 49,
        "content": "due to Chlamydophila pneumoniae , Haemophilus influenzae , Legionella pneumophila , Moraxella catarr halis , Mycoplasma",
        "metadata": {
            "section_title": "due to Chlamydophila pneumoniae , Haemophilus influenzae , Legionella pneumophila , Moraxella catarr halis , Mycoplasma"
        }
    },
    {
        "page_number": 3,
        "section_number": 50,
        "content": "pneumoniae , Staphylococcus aur eus, or Streptococcus pneumoniae in patients who require initial intravenous therapy .Sections or subsections omitted from the full prescribing",
        "metadata": {
            "section_title": "pneumoniae , Staphylococcus aur eus, or Streptococcus pneumoniae in patients who require initial intravenous therapy .Sections or subsections omitted from the full prescribing"
        }
    },
    {
        "page_number": 3,
        "section_number": 51,
        "content": "information are not listed.",
        "metadata": {
            "section_title": "information are not listed."
        }
    },
    {
        "page_number": 4,
        "section_number": 1,
        "content": "1.2 Pelvic Inflammatory Disease",
        "metadata": {
            "section_title": "1.2 Pelvic Inflammatory Disease"
        }
    },
    {
        "page_number": 4,
        "section_number": 2,
        "content": "due to Chlamydia trachomatis , Neisseria gonorr hoeae , or Mycoplasma hominis in patients who require initial intravenous",
        "metadata": {
            "section_title": "due to Chlamydia trachomatis , Neisseria gonorr hoeae , or Mycoplasma hominis in patients who require initial intravenous"
        }
    },
    {
        "page_number": 4,
        "section_number": 3,
        "content": "therapy . If anaerobic microor ganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic",
        "metadata": {
            "section_title": "therapy . If anaerobic microor ganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic"
        }
    },
    {
        "page_number": 4,
        "section_number": 4,
        "content": "activity should be administered in combination with Azithromycin.",
        "metadata": {
            "section_title": "activity should be administered in combination with Azithromycin."
        }
    },
    {
        "page_number": 4,
        "section_number": 5,
        "content": "Azithromycin for Injection, USP  should be followed by azithromycin the oral route as required [ see Dosage and",
        "metadata": {
            "section_title": "Azithromycin for Injection, USP  should be followed by azithromycin the oral route as required [ see Dosage and"
        }
    },
    {
        "page_number": 4,
        "section_number": 6,
        "content": "Administration (2) ].",
        "metadata": {
            "section_title": "Administration (2) ]."
        }
    },
    {
        "page_number": 4,
        "section_number": 7,
        "content": "1.3 Usage",
        "metadata": {
            "section_title": "1.3 Usage"
        }
    },
    {
        "page_number": 4,
        "section_number": 8,
        "content": "To reduce the development of drug-resistant bacteria and maintain the ef fectiveness of azithromycin and other antibacterial",
        "metadata": {
            "section_title": "To reduce the development of drug-resistant bacteria and maintain the ef fectiveness of azithromycin and other antibacterial"
        }
    },
    {
        "page_number": 4,
        "section_number": 9,
        "content": "drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible",
        "metadata": {
            "section_title": "drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible"
        }
    },
    {
        "page_number": 4,
        "section_number": 10,
        "content": "bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying",
        "metadata": {
            "section_title": "bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying"
        }
    },
    {
        "page_number": 4,
        "section_number": 11,
        "content": "antibacterial therapy . In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric",
        "metadata": {
            "section_title": "antibacterial therapy . In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric"
        }
    },
    {
        "page_number": 4,
        "section_number": 12,
        "content": "selection of therapy .",
        "metadata": {
            "section_title": "selection of therapy ."
        }
    },
    {
        "page_number": 4,
        "section_number": 13,
        "content": "2 DOSAGE AND ADMINISTRA TION",
        "metadata": {
            "section_title": "2 DOSAGE AND ADMINISTRA TION"
        }
    },
    {
        "page_number": 4,
        "section_number": 14,
        "content": "[see Indications and Usage (1)  and Clinical Pharmacology (12.3) ].",
        "metadata": {
            "section_title": "[see Indications and Usage (1)  and Clinical Pharmacology (12.3) ]."
        }
    },
    {
        "page_number": 4,
        "section_number": 15,
        "content": "2.1 Community-Acquir ed Pneumonia",
        "metadata": {
            "section_title": "2.1 Community-Acquir ed Pneumonia"
        }
    },
    {
        "page_number": 4,
        "section_number": 16,
        "content": "The recommended dose of Azithromycin for Injection, USP  for the treatment of adult patients with community-acquired",
        "metadata": {
            "section_title": "The recommended dose of Azithromycin for Injection, USP  for the treatment of adult patients with community-acquired"
        }
    },
    {
        "page_number": 4,
        "section_number": 17,
        "content": "pneumonia due to the indicated or ganisms is 500 mg as a single daily dose by the intravenous route for at least two days.",
        "metadata": {
            "section_title": "pneumonia due to the indicated or ganisms is 500 mg as a single daily dose by the intravenous route for at least two days."
        }
    },
    {
        "page_number": 4,
        "section_number": 18,
        "content": "Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as",
        "metadata": {
            "section_title": "Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as"
        }
    },
    {
        "page_number": 4,
        "section_number": 19,
        "content": "two 250-mg tablets to complete a 7- to 10-day course of therapy . The timing of the switch to oral therapy should be done at the",
        "metadata": {
            "section_title": "two 250-mg tablets to complete a 7- to 10-day course of therapy . The timing of the switch to oral therapy should be done at the"
        }
    },
    {
        "page_number": 4,
        "section_number": 20,
        "content": "discretion of the physician and in accordance with clinical response.",
        "metadata": {
            "section_title": "discretion of the physician and in accordance with clinical response."
        }
    },
    {
        "page_number": 4,
        "section_number": 21,
        "content": "2.2 Pelvic Inflammatory Disease",
        "metadata": {
            "section_title": "2.2 Pelvic Inflammatory Disease"
        }
    },
    {
        "page_number": 4,
        "section_number": 22,
        "content": "The recommended dose of Azithromycin for Injection, USP  for the treatment of adult patients with pelvic inflammatory",
        "metadata": {
            "section_title": "The recommended dose of Azithromycin for Injection, USP  for the treatment of adult patients with pelvic inflammatory"
        }
    },
    {
        "page_number": 4,
        "section_number": 23,
        "content": "disease due to the indicated or ganisms is 500 mg as a single daily dose by the intravenous route for one or two days.",
        "metadata": {
            "section_title": "disease due to the indicated or ganisms is 500 mg as a single daily dose by the intravenous route for one or two days."
        }
    },
    {
        "page_number": 4,
        "section_number": 24,
        "content": "Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day",
        "metadata": {
            "section_title": "Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day"
        }
    },
    {
        "page_number": 4,
        "section_number": 25,
        "content": "course of therapy . The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance",
        "metadata": {
            "section_title": "course of therapy . The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance"
        }
    },
    {
        "page_number": 4,
        "section_number": 26,
        "content": "with clinical response.",
        "metadata": {
            "section_title": "with clinical response."
        }
    },
    {
        "page_number": 4,
        "section_number": 27,
        "content": "2.3 Pr eparation of the Solution for  Intravenous Administration",
        "metadata": {
            "section_title": "2.3 Pr eparation of the Solution for  Intravenous Administration"
        }
    },
    {
        "page_number": 4,
        "section_number": 28,
        "content": "The infusate concentration and rate of infusion for Azithromycin for Injection, USP  should be either 1 mg/mL  over 3 hours or",
        "metadata": {
            "section_title": "The infusate concentration and rate of infusion for Azithromycin for Injection, USP  should be either 1 mg/mL  over 3 hours or"
        }
    },
    {
        "page_number": 4,
        "section_number": 29,
        "content": "2 mg/mL  over 1 hour . Azithromycin for Injection, USP  should not be given as a bolus or as an intramuscular injection.",
        "metadata": {
            "section_title": "2 mg/mL  over 1 hour . Azithromycin for Injection, USP  should not be given as a bolus or as an intramuscular injection."
        }
    },
    {
        "page_number": 4,
        "section_number": 30,
        "content": "Reconstitution",
        "metadata": {
            "section_title": "Reconstitution"
        }
    },
    {
        "page_number": 4,
        "section_number": 31,
        "content": "Prepare the initial solution of Azithromycin for Injection by adding 4.8 mL  of Sterile Water for Injection to the 500 mg vial and",
        "metadata": {
            "section_title": "Prepare the initial solution of Azithromycin for Injection by adding 4.8 mL  of Sterile Water for Injection to the 500 mg vial and"
        }
    },
    {
        "page_number": 4,
        "section_number": 32,
        "content": "shaking the vial until all of the drug is dissolved. Since Azithromycin for Injection is supplied under vacuum, it is",
        "metadata": {
            "section_title": "shaking the vial until all of the drug is dissolved. Since Azithromycin for Injection is supplied under vacuum, it is"
        }
    },
    {
        "page_number": 4,
        "section_number": 33,
        "content": "recommended that a standard 5 mL  (non-automated) syringe be used to ensure that the exact amount of 4.8 mL  of Sterile Water",
        "metadata": {
            "section_title": "recommended that a standard 5 mL  (non-automated) syringe be used to ensure that the exact amount of 4.8 mL  of Sterile Water"
        }
    },
    {
        "page_number": 4,
        "section_number": 34,
        "content": "is dispensed. Each mL  of reconstituted solution contains 100 mg azithromycin and 76.9 mg of anhydrous citric acid.",
        "metadata": {
            "section_title": "is dispensed. Each mL  of reconstituted solution contains 100 mg azithromycin and 76.9 mg of anhydrous citric acid."
        }
    },
    {
        "page_number": 4,
        "section_number": 35,
        "content": "Reconstituted solution is stable for 24 hours when stored below 30°C or 86°F .",
        "metadata": {
            "section_title": "Reconstituted solution is stable for 24 hours when stored below 30°C or 86°F ."
        }
    },
    {
        "page_number": 4,
        "section_number": 36,
        "content": "Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is",
        "metadata": {
            "section_title": "Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is"
        }
    },
    {
        "page_number": 4,
        "section_number": 37,
        "content": "evident in reconstituted fluids, the drug solution should be discarded.",
        "metadata": {
            "section_title": "evident in reconstituted fluids, the drug solution should be discarded."
        }
    },
    {
        "page_number": 4,
        "section_number": 38,
        "content": "Dilute this solution further prior to administration as instructed below .",
        "metadata": {
            "section_title": "Dilute this solution further prior to administration as instructed below ."
        }
    },
    {
        "page_number": 4,
        "section_number": 39,
        "content": "Dilution",
        "metadata": {
            "section_title": "Dilution"
        }
    },
    {
        "page_number": 4,
        "section_number": 40,
        "content": "To provide azithromycin over a concentration range of 1-2 mg/mL, transfer 5 mL  of the 100 mg/mL  azithromycin solution into",
        "metadata": {
            "section_title": "To provide azithromycin over a concentration range of 1-2 mg/mL, transfer 5 mL  of the 100 mg/mL  azithromycin solution into"
        }
    },
    {
        "page_number": 4,
        "section_number": 41,
        "content": "the appropriate amount of any of the diluents listed below:",
        "metadata": {
            "section_title": "the appropriate amount of any of the diluents listed below:"
        }
    },
    {
        "page_number": 4,
        "section_number": 42,
        "content": "Normal Saline (0.9% sodium chloride)",
        "metadata": {
            "section_title": "Normal Saline (0.9% sodium chloride)"
        }
    },
    {
        "page_number": 4,
        "section_number": 43,
        "content": "1/2 Normal Saline (0.45% sodium chloride)",
        "metadata": {
            "section_title": "1/2 Normal Saline (0.45% sodium chloride)"
        }
    },
    {
        "page_number": 4,
        "section_number": 44,
        "content": "5% Dextrose in Water",
        "metadata": {
            "section_title": "5% Dextrose in Water"
        }
    },
    {
        "page_number": 4,
        "section_number": 45,
        "content": "Lactated Ringer's Solution",
        "metadata": {
            "section_title": "Lactated Ringer's Solution"
        }
    },
    {
        "page_number": 4,
        "section_number": 46,
        "content": "5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride) with 20 mEq KCl",
        "metadata": {
            "section_title": "5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride) with 20 mEq KCl"
        }
    },
    {
        "page_number": 5,
        "section_number": 1,
        "content": "5% Dextrose in Lactated Ringer's Solution",
        "metadata": {
            "section_title": "5% Dextrose in Lactated Ringer's Solution"
        }
    },
    {
        "page_number": 5,
        "section_number": 2,
        "content": "5% Dextrose in 1/3 Normal Saline (0.3% sodium chloride)",
        "metadata": {
            "section_title": "5% Dextrose in 1/3 Normal Saline (0.3% sodium chloride)"
        }
    },
    {
        "page_number": 5,
        "section_number": 3,
        "content": "5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride)",
        "metadata": {
            "section_title": "5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride)"
        }
    },
    {
        "page_number": 5,
        "section_number": 4,
        "content": "Normosol -M in 5% Dextrose",
        "metadata": {
            "section_title": "Normosol -M in 5% Dextrose"
        }
    },
    {
        "page_number": 5,
        "section_number": 5,
        "content": "Normosol -R in 5% Dextrose",
        "metadata": {
            "section_title": "Normosol -R in 5% Dextrose"
        }
    },
    {
        "page_number": 5,
        "section_number": 6,
        "content": "When used with the drug reconstitution device, please reference the instructions for assembly and reconstitution.",
        "metadata": {
            "section_title": "When used with the drug reconstitution device, please reference the instructions for assembly and reconstitution."
        }
    },
    {
        "page_number": 5,
        "section_number": 7,
        "content": "Final Infusion Solution Concentration (mg/mL) Amount of Diluent (mL)",
        "metadata": {
            "section_title": "Final Infusion Solution Concentration (mg/mL) Amount of Diluent (mL)"
        }
    },
    {
        "page_number": 5,
        "section_number": 8,
        "content": "1 mg/mL 500 mL",
        "metadata": {
            "section_title": "1 mg/mL 500 mL"
        }
    },
    {
        "page_number": 5,
        "section_number": 9,
        "content": "2 mg/mL 250 mL",
        "metadata": {
            "section_title": "2 mg/mL 250 mL"
        }
    },
    {
        "page_number": 5,
        "section_number": 10,
        "content": "Other intravenous substances, additives, or medications should not be added to Azithromycin for Injection, or infused",
        "metadata": {
            "section_title": "Other intravenous substances, additives, or medications should not be added to Azithromycin for Injection, or infused"
        }
    },
    {
        "page_number": 5,
        "section_number": 11,
        "content": "simultaneously through the same intravenous line.",
        "metadata": {
            "section_title": "simultaneously through the same intravenous line."
        }
    },
    {
        "page_number": 5,
        "section_number": 12,
        "content": "Storage",
        "metadata": {
            "section_title": "Storage"
        }
    },
    {
        "page_number": 5,
        "section_number": 13,
        "content": "When diluted according to the instructions (1 mg/mL  to 2 mg/mL), Azithromycin for Injection is stable for 24 hours at or",
        "metadata": {
            "section_title": "When diluted according to the instructions (1 mg/mL  to 2 mg/mL), Azithromycin for Injection is stable for 24 hours at or"
        }
    },
    {
        "page_number": 5,
        "section_number": 14,
        "content": "below room temperature (30°C or 86°F), or for 7 days if stored under refrigeration (5°C or 41°F).",
        "metadata": {
            "section_title": "below room temperature (30°C or 86°F), or for 7 days if stored under refrigeration (5°C or 41°F)."
        }
    },
    {
        "page_number": 5,
        "section_number": 15,
        "content": "3 DOSAGE FORMS AND STRENGTHS",
        "metadata": {
            "section_title": "3 DOSAGE FORMS AND STRENGTHS"
        }
    },
    {
        "page_number": 5,
        "section_number": 16,
        "content": "Azithromycin for Injection is supplied as white to of f-white lyophilized powder in a single-dose vial equivalent to 500 mg of",
        "metadata": {
            "section_title": "Azithromycin for Injection is supplied as white to of f-white lyophilized powder in a single-dose vial equivalent to 500 mg of"
        }
    },
    {
        "page_number": 5,
        "section_number": 17,
        "content": "azithromycin for intravenous administration.",
        "metadata": {
            "section_title": "azithromycin for intravenous administration."
        }
    },
    {
        "page_number": 5,
        "section_number": 18,
        "content": "4 CONTRAINDICA TIONS",
        "metadata": {
            "section_title": "4 CONTRAINDICA TIONS"
        }
    },
    {
        "page_number": 5,
        "section_number": 19,
        "content": "4.1 Hypersensitivity",
        "metadata": {
            "section_title": "4.1 Hypersensitivity"
        }
    },
    {
        "page_number": 5,
        "section_number": 20,
        "content": "Azithromycin for Injection is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any",
        "metadata": {
            "section_title": "Azithromycin for Injection is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any"
        }
    },
    {
        "page_number": 5,
        "section_number": 21,
        "content": "macrolide or ketolide drugs.",
        "metadata": {
            "section_title": "macrolide or ketolide drugs."
        }
    },
    {
        "page_number": 5,
        "section_number": 22,
        "content": "4.2 Hepatic Dysfunction",
        "metadata": {
            "section_title": "4.2 Hepatic Dysfunction"
        }
    },
    {
        "page_number": 5,
        "section_number": 23,
        "content": "Azithromycin for Injection is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated",
        "metadata": {
            "section_title": "Azithromycin for Injection is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated"
        }
    },
    {
        "page_number": 5,
        "section_number": 24,
        "content": "with prior use of azithromycin.",
        "metadata": {
            "section_title": "with prior use of azithromycin."
        }
    },
    {
        "page_number": 5,
        "section_number": 25,
        "content": "5 WARNINGS AND PRECAUTIONS",
        "metadata": {
            "section_title": "5 WARNINGS AND PRECAUTIONS"
        }
    },
    {
        "page_number": 5,
        "section_number": 26,
        "content": "5.1 Hypersensitivity",
        "metadata": {
            "section_title": "5.1 Hypersensitivity"
        }
    },
    {
        "page_number": 5,
        "section_number": 27,
        "content": "Serious aller gic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized",
        "metadata": {
            "section_title": "Serious aller gic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized"
        }
    },
    {
        "page_number": 5,
        "section_number": 28,
        "content": "Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported in patients",
        "metadata": {
            "section_title": "Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported in patients"
        }
    },
    {
        "page_number": 5,
        "section_number": 29,
        "content": "on azithromycin therapy [ see Contraindications (4.1) ].",
        "metadata": {
            "section_title": "on azithromycin therapy [ see Contraindications (4.1) ]."
        }
    },
    {
        "page_number": 5,
        "section_number": 30,
        "content": "Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been",
        "metadata": {
            "section_title": "Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been"
        }
    },
    {
        "page_number": 5,
        "section_number": 31,
        "content": "reported. Despite initially successful symptomatic treatment of the aller gic symptoms, when symptomatic therapy was",
        "metadata": {
            "section_title": "reported. Despite initially successful symptomatic treatment of the aller gic symptoms, when symptomatic therapy was"
        }
    },
    {
        "page_number": 5,
        "section_number": 32,
        "content": "discontinued, the aller gic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These",
        "metadata": {
            "section_title": "discontinued, the aller gic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These"
        }
    },
    {
        "page_number": 5,
        "section_number": 33,
        "content": "patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long",
        "metadata": {
            "section_title": "patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long"
        }
    },
    {
        "page_number": 5,
        "section_number": 34,
        "content": "tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.",
        "metadata": {
            "section_title": "tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present."
        }
    },
    {
        "page_number": 5,
        "section_number": 35,
        "content": "If an aller gic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should",
        "metadata": {
            "section_title": "If an aller gic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should"
        }
    },
    {
        "page_number": 5,
        "section_number": 36,
        "content": "be aware that the aller gic symptoms may reappear after symptomatic therapy has been discontinued.",
        "metadata": {
            "section_title": "be aware that the aller gic symptoms may reappear after symptomatic therapy has been discontinued."
        }
    },
    {
        "page_number": 5,
        "section_number": 37,
        "content": "5.2 Hepatotoxicity",
        "metadata": {
            "section_title": "5.2 Hepatotoxicity"
        }
    },
    {
        "page_number": 5,
        "section_number": 38,
        "content": "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of",
        "metadata": {
            "section_title": "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of"
        }
    },
    {
        "page_number": 5,
        "section_number": 39,
        "content": "which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur .®",
        "metadata": {
            "section_title": "which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur .®"
        }
    },
    {
        "page_number": 5,
        "section_number": 40,
        "content": "®",
        "metadata": {
            "section_title": "®"
        }
    },
    {
        "page_number": 6,
        "section_number": 1,
        "content": "5.3 Infantile Hypertr ophic Pyloric Stenosis (IHPS)",
        "metadata": {
            "section_title": "5.3 Infantile Hypertr ophic Pyloric Stenosis (IHPS)"
        }
    },
    {
        "page_number": 6,
        "section_number": 2,
        "content": "Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and",
        "metadata": {
            "section_title": "Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and"
        }
    },
    {
        "page_number": 6,
        "section_number": 3,
        "content": "caregivers to contact their physician if vomiting or irritability with feeding occurs.",
        "metadata": {
            "section_title": "caregivers to contact their physician if vomiting or irritability with feeding occurs."
        }
    },
    {
        "page_number": 6,
        "section_number": 4,
        "content": "5.4 QT  Prolongation",
        "metadata": {
            "section_title": "5.4 QT  Prolongation"
        }
    },
    {
        "page_number": 6,
        "section_number": 5,
        "content": "Prolonged cardiac repolarization and QT  interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes,",
        "metadata": {
            "section_title": "Prolonged cardiac repolarization and QT  interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes,"
        }
    },
    {
        "page_number": 6,
        "section_number": 6,
        "content": "have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously",
        "metadata": {
            "section_title": "have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously"
        }
    },
    {
        "page_number": 6,
        "section_number": 7,
        "content": "reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT",
        "metadata": {
            "section_title": "reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT"
        }
    },
    {
        "page_number": 6,
        "section_number": 8,
        "content": "prolongation, which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:",
        "metadata": {
            "section_title": "prolongation, which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:"
        }
    },
    {
        "page_number": 6,
        "section_number": 9,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 6,
        "section_number": 10,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 6,
        "section_number": 11,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 6,
        "section_number": 12,
        "content": "Elderly patients may be more susceptible to drug-associated ef fects on the QT  interval.",
        "metadata": {
            "section_title": "Elderly patients may be more susceptible to drug-associated ef fects on the QT  interval."
        }
    },
    {
        "page_number": 6,
        "section_number": 13,
        "content": "5.5 Cardiovascular  Death",
        "metadata": {
            "section_title": "5.5 Cardiovascular  Death"
        }
    },
    {
        "page_number": 6,
        "section_number": 14,
        "content": "Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular",
        "metadata": {
            "section_title": "Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular"
        }
    },
    {
        "page_number": 6,
        "section_number": 15,
        "content": "death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular",
        "metadata": {
            "section_title": "death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular"
        }
    },
    {
        "page_number": 6,
        "section_number": 16,
        "content": "mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses. This potential risk was",
        "metadata": {
            "section_title": "mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses. This potential risk was"
        }
    },
    {
        "page_number": 6,
        "section_number": 17,
        "content": "noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with",
        "metadata": {
            "section_title": "noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with"
        }
    },
    {
        "page_number": 6,
        "section_number": 18,
        "content": "preexisting cardiovascular diseases. The data in these observational studies are insuf ficient to establish or exclude a causal",
        "metadata": {
            "section_title": "preexisting cardiovascular diseases. The data in these observational studies are insuf ficient to establish or exclude a causal"
        }
    },
    {
        "page_number": 6,
        "section_number": 19,
        "content": "relationship between acute cardiovascular death and azithromycin use. Consider balancing this potential risk with treatment",
        "metadata": {
            "section_title": "relationship between acute cardiovascular death and azithromycin use. Consider balancing this potential risk with treatment"
        }
    },
    {
        "page_number": 6,
        "section_number": 20,
        "content": "benefits when prescribing azithromycin .",
        "metadata": {
            "section_title": "benefits when prescribing azithromycin ."
        }
    },
    {
        "page_number": 6,
        "section_number": 21,
        "content": "5.6 Clostridioides dif ficile -Associated Diarrhea",
        "metadata": {
            "section_title": "5.6 Clostridioides dif ficile -Associated Diarrhea"
        }
    },
    {
        "page_number": 6,
        "section_number": 22,
        "content": "Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including",
        "metadata": {
            "section_title": "Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including"
        }
    },
    {
        "page_number": 6,
        "section_number": 23,
        "content": "Azithromycin for Injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents",
        "metadata": {
            "section_title": "Azithromycin for Injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents"
        }
    },
    {
        "page_number": 6,
        "section_number": 24,
        "content": "alters the normal flora of the colon leading to over growth of C. difficile .",
        "metadata": {
            "section_title": "alters the normal flora of the colon leading to over growth of C. difficile ."
        }
    },
    {
        "page_number": 6,
        "section_number": 25,
        "content": "C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C.",
        "metadata": {
            "section_title": "C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C."
        }
    },
    {
        "page_number": 6,
        "section_number": 26,
        "content": "difficile cause increased morbidity and mortality , as these infections can be refractory to antibacterial therapy and may require",
        "metadata": {
            "section_title": "difficile cause increased morbidity and mortality , as these infections can be refractory to antibacterial therapy and may require"
        }
    },
    {
        "page_number": 6,
        "section_number": 27,
        "content": "colectomy . CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical",
        "metadata": {
            "section_title": "colectomy . CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical"
        }
    },
    {
        "page_number": 6,
        "section_number": 28,
        "content": "history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.",
        "metadata": {
            "section_title": "history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents."
        }
    },
    {
        "page_number": 6,
        "section_number": 29,
        "content": "If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.",
        "metadata": {
            "section_title": "If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued."
        }
    },
    {
        "page_number": 6,
        "section_number": 30,
        "content": "Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile  and sur gical",
        "metadata": {
            "section_title": "Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile  and sur gical"
        }
    },
    {
        "page_number": 6,
        "section_number": 31,
        "content": "evaluation should be instituted as clinically indicated.",
        "metadata": {
            "section_title": "evaluation should be instituted as clinically indicated."
        }
    },
    {
        "page_number": 6,
        "section_number": 32,
        "content": "5.7 Exacerbation of Myasthenia Gravis",
        "metadata": {
            "section_title": "5.7 Exacerbation of Myasthenia Gravis"
        }
    },
    {
        "page_number": 6,
        "section_number": 33,
        "content": "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients",
        "metadata": {
            "section_title": "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients"
        }
    },
    {
        "page_number": 6,
        "section_number": 34,
        "content": "receiving azithromycin therapy .",
        "metadata": {
            "section_title": "receiving azithromycin therapy ."
        }
    },
    {
        "page_number": 6,
        "section_number": 35,
        "content": "5.8 Infusion Site Reactions",
        "metadata": {
            "section_title": "5.8 Infusion Site Reactions"
        }
    },
    {
        "page_number": 6,
        "section_number": 36,
        "content": "Azithromycin for Injection should be reconstituted and diluted as directed and administered as an intravenous infusion over not",
        "metadata": {
            "section_title": "Azithromycin for Injection should be reconstituted and diluted as directed and administered as an intravenous infusion over not"
        }
    },
    {
        "page_number": 6,
        "section_number": 37,
        "content": "less than 60 minutes [ see Dosage and Administration (2) ].",
        "metadata": {
            "section_title": "less than 60 minutes [ see Dosage and Administration (2) ]."
        }
    },
    {
        "page_number": 6,
        "section_number": 38,
        "content": "Local IV  site reactions have been reported with the intravenous administration of azithromycin. The incidence and severity of",
        "metadata": {
            "section_title": "Local IV  site reactions have been reported with the intravenous administration of azithromycin. The incidence and severity of"
        }
    },
    {
        "page_number": 6,
        "section_number": 39,
        "content": "these reactions were the same when 500 mg azithromycin was given over 1 hour (2 mg/mL  as 250 mL  infusion) or over 3",
        "metadata": {
            "section_title": "these reactions were the same when 500 mg azithromycin was given over 1 hour (2 mg/mL  as 250 mL  infusion) or over 3"
        }
    },
    {
        "page_number": 6,
        "section_number": 40,
        "content": "hours (1 mg/mL  as 500 mL  infusion) [ see Adverse Reactions (6) ]. All volunteers who received infusate concentrations above 2",
        "metadata": {
            "section_title": "hours (1 mg/mL  as 500 mL  infusion) [ see Adverse Reactions (6) ]. All volunteers who received infusate concentrations above 2"
        }
    },
    {
        "page_number": 6,
        "section_number": 41,
        "content": "mg/mL  experienced local IV  site reactions and, therefore, higher concentrations should be avoided.patients with known prolongation of the QT  interval, a history of torsades de pointes, congenital long QT  syndrome,",
        "metadata": {
            "section_title": "mg/mL  experienced local IV  site reactions and, therefore, higher concentrations should be avoided.patients with known prolongation of the QT  interval, a history of torsades de pointes, congenital long QT  syndrome,"
        }
    },
    {
        "page_number": 6,
        "section_number": 42,
        "content": "bradyarrhythmias or uncompensated heart failure",
        "metadata": {
            "section_title": "bradyarrhythmias or uncompensated heart failure"
        }
    },
    {
        "page_number": 6,
        "section_number": 43,
        "content": "patients on drugs known to prolong the QT  interval",
        "metadata": {
            "section_title": "patients on drugs known to prolong the QT  interval"
        }
    },
    {
        "page_number": 6,
        "section_number": 44,
        "content": "patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically",
        "metadata": {
            "section_title": "patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically"
        }
    },
    {
        "page_number": 6,
        "section_number": 45,
        "content": "significant bradycardia and in patients receiving Class IA  (quinidine, procainamide) or Class III (dofetilide, amiodarone,",
        "metadata": {
            "section_title": "significant bradycardia and in patients receiving Class IA  (quinidine, procainamide) or Class III (dofetilide, amiodarone,"
        }
    },
    {
        "page_number": 6,
        "section_number": 46,
        "content": "sotalol) antiarrhythmic agents.",
        "metadata": {
            "section_title": "sotalol) antiarrhythmic agents."
        }
    },
    {
        "page_number": 7,
        "section_number": 1,
        "content": "5.9 Development of Drug-Resistant Bacteria",
        "metadata": {
            "section_title": "5.9 Development of Drug-Resistant Bacteria"
        }
    },
    {
        "page_number": 7,
        "section_number": 2,
        "content": "Prescribing Azithromycin for Injection in the absence of a proven or strongly suspected bacterial infection is unlikely to",
        "metadata": {
            "section_title": "Prescribing Azithromycin for Injection in the absence of a proven or strongly suspected bacterial infection is unlikely to"
        }
    },
    {
        "page_number": 7,
        "section_number": 3,
        "content": "provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.",
        "metadata": {
            "section_title": "provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."
        }
    },
    {
        "page_number": 7,
        "section_number": 4,
        "content": "6 ADVERSE REACTIONS",
        "metadata": {
            "section_title": "6 ADVERSE REACTIONS"
        }
    },
    {
        "page_number": 7,
        "section_number": 5,
        "content": "The following clinically significant adverse reactions are described elsewhere in labeling:",
        "metadata": {
            "section_title": "The following clinically significant adverse reactions are described elsewhere in labeling:"
        }
    },
    {
        "page_number": 7,
        "section_number": 6,
        "content": "Hypersensitivity [see Warnings and Pr ecautions (5.1) ]",
        "metadata": {
            "section_title": "Hypersensitivity [see Warnings and Pr ecautions (5.1) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 7,
        "content": "Hepatotoxicity [see Warnings and Pr ecautions (5.2) ]",
        "metadata": {
            "section_title": "Hepatotoxicity [see Warnings and Pr ecautions (5.2) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 8,
        "content": "Infantile Hypertrophic Pyloric Stenosis (IHPS) [see Warnings and Pr ecautions (5.3) ]",
        "metadata": {
            "section_title": "Infantile Hypertrophic Pyloric Stenosis (IHPS) [see Warnings and Pr ecautions (5.3) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 9,
        "content": "QT Prolongation [see Warnings and Pr ecautions (5.4) ]",
        "metadata": {
            "section_title": "QT Prolongation [see Warnings and Pr ecautions (5.4) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 10,
        "content": "Cardiovascular Death [see Warnings and Pr ecautions (5.5) ]",
        "metadata": {
            "section_title": "Cardiovascular Death [see Warnings and Pr ecautions (5.5) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 11,
        "content": "Clostridioides difficile- Associated Diarrhea (CDAD) [see Warnings and Pr ecautions (5.6) ]",
        "metadata": {
            "section_title": "Clostridioides difficile- Associated Diarrhea (CDAD) [see Warnings and Pr ecautions (5.6) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 12,
        "content": "Exacerbation of Myasthenia Gravis [see Warnings and Pr ecautions (5.7) ]",
        "metadata": {
            "section_title": "Exacerbation of Myasthenia Gravis [see Warnings and Pr ecautions (5.7) ]"
        }
    },
    {
        "page_number": 7,
        "section_number": 13,
        "content": "6.1 Clinical Trials Experience",
        "metadata": {
            "section_title": "6.1 Clinical Trials Experience"
        }
    },
    {
        "page_number": 7,
        "section_number": 14,
        "content": "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a",
        "metadata": {
            "section_title": "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a"
        }
    },
    {
        "page_number": 7,
        "section_number": 15,
        "content": "drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in",
        "metadata": {
            "section_title": "drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in"
        }
    },
    {
        "page_number": 7,
        "section_number": 16,
        "content": "practice.",
        "metadata": {
            "section_title": "practice."
        }
    },
    {
        "page_number": 7,
        "section_number": 17,
        "content": "In clinical trials of intravenous azithromycin for community-acquired pneumonia, in which 2 to 5 IV  doses were given, the",
        "metadata": {
            "section_title": "In clinical trials of intravenous azithromycin for community-acquired pneumonia, in which 2 to 5 IV  doses were given, the"
        }
    },
    {
        "page_number": 7,
        "section_number": 18,
        "content": "reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. The",
        "metadata": {
            "section_title": "reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. The"
        }
    },
    {
        "page_number": 7,
        "section_number": 19,
        "content": "majority of patients in these trials had one or more co-morbid diseases and were receiving concomitant medications.",
        "metadata": {
            "section_title": "majority of patients in these trials had one or more co-morbid diseases and were receiving concomitant medications."
        }
    },
    {
        "page_number": 7,
        "section_number": 20,
        "content": "Approximately 1.2% of the patients discontinued intravenous Azithromycin for Injection therapy and a total of 2.4%",
        "metadata": {
            "section_title": "Approximately 1.2% of the patients discontinued intravenous Azithromycin for Injection therapy and a total of 2.4%"
        }
    },
    {
        "page_number": 7,
        "section_number": 21,
        "content": "discontinued azithromycin therapy by either the intravenous or oral route because of clinical or laboratory side ef fects.",
        "metadata": {
            "section_title": "discontinued azithromycin therapy by either the intravenous or oral route because of clinical or laboratory side ef fects."
        }
    },
    {
        "page_number": 7,
        "section_number": 22,
        "content": "In clinical trials conducted in patients with pelvic inflammatory disease, in which 1 to 2 IV  doses were given, 2% of women",
        "metadata": {
            "section_title": "In clinical trials conducted in patients with pelvic inflammatory disease, in which 1 to 2 IV  doses were given, 2% of women"
        }
    },
    {
        "page_number": 7,
        "section_number": 23,
        "content": "who received monotherapy with azithromycin and 4% who received azithromycin plus metronidazole discontinued therapy",
        "metadata": {
            "section_title": "who received monotherapy with azithromycin and 4% who received azithromycin plus metronidazole discontinued therapy"
        }
    },
    {
        "page_number": 7,
        "section_number": 24,
        "content": "due to clinical side ef fects.",
        "metadata": {
            "section_title": "due to clinical side ef fects."
        }
    },
    {
        "page_number": 7,
        "section_number": 25,
        "content": "Clinical adverse reactions leading to discontinuations from these studies were gastrointestinal (abdominal pain, nausea,",
        "metadata": {
            "section_title": "Clinical adverse reactions leading to discontinuations from these studies were gastrointestinal (abdominal pain, nausea,"
        }
    },
    {
        "page_number": 7,
        "section_number": 26,
        "content": "vomiting, diarrhea) and rashes; laboratory side ef fects leading to discontinuation were increases in transaminase levels and/or",
        "metadata": {
            "section_title": "vomiting, diarrhea) and rashes; laboratory side ef fects leading to discontinuation were increases in transaminase levels and/or"
        }
    },
    {
        "page_number": 7,
        "section_number": 27,
        "content": "alkaline phosphatase levels.",
        "metadata": {
            "section_title": "alkaline phosphatase levels."
        }
    },
    {
        "page_number": 7,
        "section_number": 28,
        "content": "Overall, the most common adverse reactions associated with treatment in adult patients who received IV/Oral Azithromycin in",
        "metadata": {
            "section_title": "Overall, the most common adverse reactions associated with treatment in adult patients who received IV/Oral Azithromycin in"
        }
    },
    {
        "page_number": 7,
        "section_number": 29,
        "content": "studies of community-acquired pneumonia were related to the gastrointestinal system with diarrhea/loose stools (4.3%), nausea",
        "metadata": {
            "section_title": "studies of community-acquired pneumonia were related to the gastrointestinal system with diarrhea/loose stools (4.3%), nausea"
        }
    },
    {
        "page_number": 7,
        "section_number": 30,
        "content": "(3.9%), abdominal pain (2.7%) and vomiting (1.4%) being the most frequently reported.",
        "metadata": {
            "section_title": "(3.9%), abdominal pain (2.7%) and vomiting (1.4%) being the most frequently reported."
        }
    },
    {
        "page_number": 7,
        "section_number": 31,
        "content": "Approximately 12% of patients experienced a side ef fect related to the intravenous infusion; most common were pain at the",
        "metadata": {
            "section_title": "Approximately 12% of patients experienced a side ef fect related to the intravenous infusion; most common were pain at the"
        }
    },
    {
        "page_number": 7,
        "section_number": 32,
        "content": "injection site (6.5%) and local inflammation (3.1%).",
        "metadata": {
            "section_title": "injection site (6.5%) and local inflammation (3.1%)."
        }
    },
    {
        "page_number": 7,
        "section_number": 33,
        "content": "The most common adverse reactions associated with treatment in adult women who received IV/Oral Azithromycin in trials of",
        "metadata": {
            "section_title": "The most common adverse reactions associated with treatment in adult women who received IV/Oral Azithromycin in trials of"
        }
    },
    {
        "page_number": 7,
        "section_number": 34,
        "content": "pelvic inflammatory disease were related to the gastrointestinal system. Diarrhea (8.5%) and nausea (6.6%) were most",
        "metadata": {
            "section_title": "pelvic inflammatory disease were related to the gastrointestinal system. Diarrhea (8.5%) and nausea (6.6%) were most"
        }
    },
    {
        "page_number": 7,
        "section_number": 35,
        "content": "commonly reported, followed by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus (1.9%). When",
        "metadata": {
            "section_title": "commonly reported, followed by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus (1.9%). When"
        }
    },
    {
        "page_number": 7,
        "section_number": 36,
        "content": "azithromycin was co-administered with metronidazole in these trials, a higher proportion of women experienced adverse",
        "metadata": {
            "section_title": "azithromycin was co-administered with metronidazole in these trials, a higher proportion of women experienced adverse"
        }
    },
    {
        "page_number": 7,
        "section_number": 37,
        "content": "reactions of nausea (10.3%), abdominal pain (3.7%), vomiting (2.8%), infusion site reaction, stomatitis, dizziness, or dyspnea",
        "metadata": {
            "section_title": "reactions of nausea (10.3%), abdominal pain (3.7%), vomiting (2.8%), infusion site reaction, stomatitis, dizziness, or dyspnea"
        }
    },
    {
        "page_number": 7,
        "section_number": 38,
        "content": "(all at 1.9%).",
        "metadata": {
            "section_title": "(all at 1.9%)."
        }
    },
    {
        "page_number": 7,
        "section_number": 39,
        "content": "Adverse reactions that occurred with a frequency of 1% or less included the following:",
        "metadata": {
            "section_title": "Adverse reactions that occurred with a frequency of 1% or less included the following:"
        }
    },
    {
        "page_number": 7,
        "section_number": 40,
        "content": "Gastr ointestinal: Dyspepsia, flatulence, mucositis, oral moniliasis and gastritis.",
        "metadata": {
            "section_title": "Gastr ointestinal: Dyspepsia, flatulence, mucositis, oral moniliasis and gastritis."
        }
    },
    {
        "page_number": 7,
        "section_number": 41,
        "content": "Nervous system: Headache, somnolence.",
        "metadata": {
            "section_title": "Nervous system: Headache, somnolence."
        }
    },
    {
        "page_number": 7,
        "section_number": 42,
        "content": "Allergic: Bronchospasm.",
        "metadata": {
            "section_title": "Allergic: Bronchospasm."
        }
    },
    {
        "page_number": 7,
        "section_number": 43,
        "content": "Special senses: Taste perversion.",
        "metadata": {
            "section_title": "Special senses: Taste perversion."
        }
    },
    {
        "page_number": 7,
        "section_number": 44,
        "content": "6.2 Postmarketing Experience",
        "metadata": {
            "section_title": "6.2 Postmarketing Experience"
        }
    },
    {
        "page_number": 7,
        "section_number": 45,
        "content": "The following adverse reactions have been identified during post-approval use of azithromycin. Because these reactions are",
        "metadata": {
            "section_title": "The following adverse reactions have been identified during post-approval use of azithromycin. Because these reactions are"
        }
    },
    {
        "page_number": 7,
        "section_number": 46,
        "content": "reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or",
        "metadata": {
            "section_title": "reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or"
        }
    },
    {
        "page_number": 7,
        "section_number": 47,
        "content": "establish a causal relationship to drug exposure.",
        "metadata": {
            "section_title": "establish a causal relationship to drug exposure."
        }
    },
    {
        "page_number": 8,
        "section_number": 1,
        "content": "Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a",
        "metadata": {
            "section_title": "Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a"
        }
    },
    {
        "page_number": 8,
        "section_number": 2,
        "content": "causal relationship may not be established include:",
        "metadata": {
            "section_title": "causal relationship may not be established include:"
        }
    },
    {
        "page_number": 8,
        "section_number": 3,
        "content": "Allergic:  Arthralgia, edema, urticaria and angioedema.",
        "metadata": {
            "section_title": "Allergic:  Arthralgia, edema, urticaria and angioedema."
        }
    },
    {
        "page_number": 8,
        "section_number": 4,
        "content": "Cardiovascular:  Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT  prolongation,",
        "metadata": {
            "section_title": "Cardiovascular:  Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT  prolongation,"
        }
    },
    {
        "page_number": 8,
        "section_number": 5,
        "content": "torsades de pointes, and cardiovascular death.",
        "metadata": {
            "section_title": "torsades de pointes, and cardiovascular death."
        }
    },
    {
        "page_number": 8,
        "section_number": 6,
        "content": "Gastr ointestinal:  Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis,",
        "metadata": {
            "section_title": "Gastr ointestinal:  Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis,"
        }
    },
    {
        "page_number": 8,
        "section_number": 7,
        "content": "oral candidiasis, pyloric stenosis, and reports of tongue discoloration.",
        "metadata": {
            "section_title": "oral candidiasis, pyloric stenosis, and reports of tongue discoloration."
        }
    },
    {
        "page_number": 8,
        "section_number": 8,
        "content": "General:  Asthenia, paresthesia, fatigue, malaise and anaphylaxis (including fatalities).",
        "metadata": {
            "section_title": "General:  Asthenia, paresthesia, fatigue, malaise and anaphylaxis (including fatalities)."
        }
    },
    {
        "page_number": 8,
        "section_number": 9,
        "content": "Genitourinary:  Interstitial nephritis and acute renal failure and vaginitis.",
        "metadata": {
            "section_title": "Genitourinary:  Interstitial nephritis and acute renal failure and vaginitis."
        }
    },
    {
        "page_number": 8,
        "section_number": 10,
        "content": "Hematopoietic:  Thrombocytopenia.",
        "metadata": {
            "section_title": "Hematopoietic:  Thrombocytopenia."
        }
    },
    {
        "page_number": 8,
        "section_number": 11,
        "content": "Liver/biliary:  Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure, [ see Warnings and",
        "metadata": {
            "section_title": "Liver/biliary:  Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure, [ see Warnings and"
        }
    },
    {
        "page_number": 8,
        "section_number": 12,
        "content": "Precautions (5.2) ].",
        "metadata": {
            "section_title": "Precautions (5.2) ]."
        }
    },
    {
        "page_number": 8,
        "section_number": 13,
        "content": "Nervous system:  Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity , nervousness, agitation and syncope.",
        "metadata": {
            "section_title": "Nervous system:  Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity , nervousness, agitation and syncope."
        }
    },
    {
        "page_number": 8,
        "section_number": 14,
        "content": "Psychiatric:  Aggressive reaction and anxiety .",
        "metadata": {
            "section_title": "Psychiatric:  Aggressive reaction and anxiety ."
        }
    },
    {
        "page_number": 8,
        "section_number": 15,
        "content": "Skin/appendages:  Pruritus, serious skin reactions including, erythema multiforme, AGEP , Stevens-Johnson syndrome, toxic",
        "metadata": {
            "section_title": "Skin/appendages:  Pruritus, serious skin reactions including, erythema multiforme, AGEP , Stevens-Johnson syndrome, toxic"
        }
    },
    {
        "page_number": 8,
        "section_number": 16,
        "content": "epidermal necrolysis, and DRESS.",
        "metadata": {
            "section_title": "epidermal necrolysis, and DRESS."
        }
    },
    {
        "page_number": 8,
        "section_number": 17,
        "content": "Special senses: Hearing disturbances including hearing loss, deafness and/or tinnitus and reports of taste/smell perversion",
        "metadata": {
            "section_title": "Special senses: Hearing disturbances including hearing loss, deafness and/or tinnitus and reports of taste/smell perversion"
        }
    },
    {
        "page_number": 8,
        "section_number": 18,
        "content": "and/or loss.",
        "metadata": {
            "section_title": "and/or loss."
        }
    },
    {
        "page_number": 8,
        "section_number": 19,
        "content": "6.3 Laboratory Abnormalities",
        "metadata": {
            "section_title": "6.3 Laboratory Abnormalities"
        }
    },
    {
        "page_number": 8,
        "section_number": 20,
        "content": "Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows:",
        "metadata": {
            "section_title": "Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows:"
        }
    },
    {
        "page_number": 8,
        "section_number": 21,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 8,
        "section_number": 22,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 8,
        "section_number": 23,
        "content": "•",
        "metadata": {
            "section_title": "•"
        }
    },
    {
        "page_number": 8,
        "section_number": 24,
        "content": "When follow-up was provided, changes in laboratory tests appeared to be reversible.",
        "metadata": {
            "section_title": "When follow-up was provided, changes in laboratory tests appeared to be reversible."
        }
    },
    {
        "page_number": 8,
        "section_number": 25,
        "content": "In multiple-dose clinical trials involving more than 750 patients treated with azithromycin (IV/Oral), less than 2% of patients",
        "metadata": {
            "section_title": "In multiple-dose clinical trials involving more than 750 patients treated with azithromycin (IV/Oral), less than 2% of patients"
        }
    },
    {
        "page_number": 8,
        "section_number": 26,
        "content": "discontinued azithromycin therapy because of treatment-related liver enzyme abnormalities.",
        "metadata": {
            "section_title": "discontinued azithromycin therapy because of treatment-related liver enzyme abnormalities."
        }
    },
    {
        "page_number": 8,
        "section_number": 27,
        "content": "7 DRUG INTERACTIONS",
        "metadata": {
            "section_title": "7 DRUG INTERACTIONS"
        }
    },
    {
        "page_number": 8,
        "section_number": 28,
        "content": "7.1 Nelfinavir",
        "metadata": {
            "section_title": "7.1 Nelfinavir"
        }
    },
    {
        "page_number": 8,
        "section_number": 29,
        "content": "Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum",
        "metadata": {
            "section_title": "Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum"
        }
    },
    {
        "page_number": 8,
        "section_number": 30,
        "content": "concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with",
        "metadata": {
            "section_title": "concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with"
        }
    },
    {
        "page_number": 8,
        "section_number": 31,
        "content": "nelfinavir , close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing",
        "metadata": {
            "section_title": "nelfinavir , close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing"
        }
    },
    {
        "page_number": 8,
        "section_number": 32,
        "content": "impairment, is warranted [ see Adverse Reactions (6) ].",
        "metadata": {
            "section_title": "impairment, is warranted [ see Adverse Reactions (6) ]."
        }
    },
    {
        "page_number": 8,
        "section_number": 33,
        "content": "7.2 Warfarin",
        "metadata": {
            "section_title": "7.2 Warfarin"
        }
    },
    {
        "page_number": 8,
        "section_number": 34,
        "content": "Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the ef fects of oral",
        "metadata": {
            "section_title": "Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the ef fects of oral"
        }
    },
    {
        "page_number": 8,
        "section_number": 35,
        "content": "anticoagulants such as warfarin, although the prothrombin time was not af fected in the dedicated drug interaction study with",
        "metadata": {
            "section_title": "anticoagulants such as warfarin, although the prothrombin time was not af fected in the dedicated drug interaction study with"
        }
    },
    {
        "page_number": 8,
        "section_number": 36,
        "content": "azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and",
        "metadata": {
            "section_title": "azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and"
        }
    },
    {
        "page_number": 8,
        "section_number": 37,
        "content": "oral anticoagulants concomitantly .",
        "metadata": {
            "section_title": "oral anticoagulants concomitantly ."
        }
    },
    {
        "page_number": 8,
        "section_number": 38,
        "content": "7.3 Potential Drug-Drug Interaction with Macr olides",
        "metadata": {
            "section_title": "7.3 Potential Drug-Drug Interaction with Macr olides"
        }
    },
    {
        "page_number": 8,
        "section_number": 39,
        "content": "Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug",
        "metadata": {
            "section_title": "Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug"
        }
    },
    {
        "page_number": 8,
        "section_number": 40,
        "content": "interaction studies have been performed to evaluate potential drug-drug interaction. However , drug interactions have been",
        "metadata": {
            "section_title": "interaction studies have been performed to evaluate potential drug-drug interaction. However , drug interactions have been"
        }
    },
    {
        "page_number": 8,
        "section_number": 41,
        "content": "observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine",
        "metadata": {
            "section_title": "observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine"
        }
    },
    {
        "page_number": 8,
        "section_number": 42,
        "content": "or phenytoin are used with azithromycin careful monitoring of patients is advised.",
        "metadata": {
            "section_title": "or phenytoin are used with azithromycin careful monitoring of patients is advised."
        }
    },
    {
        "page_number": 8,
        "section_number": 43,
        "content": "8 USE IN SPECIFIC POPULA TIONS",
        "metadata": {
            "section_title": "8 USE IN SPECIFIC POPULA TIONS"
        }
    },
    {
        "page_number": 8,
        "section_number": 44,
        "content": "8.1 Pr egnancy",
        "metadata": {
            "section_title": "8.1 Pr egnancy"
        }
    },
    {
        "page_number": 8,
        "section_number": 45,
        "content": "Risk Summaryelevated ALT (SGPT), AST (SGOT), creatinine (4 to 6%)",
        "metadata": {
            "section_title": "Risk Summaryelevated ALT (SGPT), AST (SGOT), creatinine (4 to 6%)"
        }
    },
    {
        "page_number": 8,
        "section_number": 46,
        "content": "elevated LDH, bilirubin (1 to 3%)",
        "metadata": {
            "section_title": "elevated LDH, bilirubin (1 to 3%)"
        }
    },
    {
        "page_number": 8,
        "section_number": 47,
        "content": "leukopenia, neutropenia, decreased platelet count and elevated serum alkaline phosphatase (less than 1%)",
        "metadata": {
            "section_title": "leukopenia, neutropenia, decreased platelet count and elevated serum alkaline phosphatase (less than 1%)"
        }
    },
    {
        "page_number": 9,
        "section_number": 1,
        "content": "Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant",
        "metadata": {
            "section_title": "Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant"
        }
    },
    {
        "page_number": 9,
        "section_number": 2,
        "content": "women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal",
        "metadata": {
            "section_title": "women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal"
        }
    },
    {
        "page_number": 9,
        "section_number": 3,
        "content": "outcomes (see Data ). Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced",
        "metadata": {
            "section_title": "outcomes (see Data ). Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced"
        }
    },
    {
        "page_number": 9,
        "section_number": 4,
        "content": "fetal malformations at doses up to 4, 2, and 2 times, respectively , an adult human daily dose of 500 mg based on body surface",
        "metadata": {
            "section_title": "fetal malformations at doses up to 4, 2, and 2 times, respectively , an adult human daily dose of 500 mg based on body surface"
        }
    },
    {
        "page_number": 9,
        "section_number": 5,
        "content": "area. Decreased viability and delayed development were observed in the of fspring of pregnant rats administered azithromycin",
        "metadata": {
            "section_title": "area. Decreased viability and delayed development were observed in the of fspring of pregnant rats administered azithromycin"
        }
    },
    {
        "page_number": 9,
        "section_number": 6,
        "content": "from day 6 of pregnancy through weaning at a dose equivalent to 4 times an adult human daily dose of 500 mg based on body",
        "metadata": {
            "section_title": "from day 6 of pregnancy through weaning at a dose equivalent to 4 times an adult human daily dose of 500 mg based on body"
        }
    },
    {
        "page_number": 9,
        "section_number": 7,
        "content": "surface area (see Data ).",
        "metadata": {
            "section_title": "surface area (see Data )."
        }
    },
    {
        "page_number": 9,
        "section_number": 8,
        "content": "The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All",
        "metadata": {
            "section_title": "The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All"
        }
    },
    {
        "page_number": 9,
        "section_number": 9,
        "content": "pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the",
        "metadata": {
            "section_title": "pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the"
        }
    },
    {
        "page_number": 9,
        "section_number": 10,
        "content": "estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to",
        "metadata": {
            "section_title": "estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to"
        }
    },
    {
        "page_number": 9,
        "section_number": 11,
        "content": "20%, respectively .",
        "metadata": {
            "section_title": "20%, respectively ."
        }
    },
    {
        "page_number": 9,
        "section_number": 12,
        "content": "Data",
        "metadata": {
            "section_title": "Data"
        }
    },
    {
        "page_number": 9,
        "section_number": 13,
        "content": "Human Data",
        "metadata": {
            "section_title": "Human Data"
        }
    },
    {
        "page_number": 9,
        "section_number": 14,
        "content": "Available data from published observational studies, case series and case reports over several decades do not suggest an",
        "metadata": {
            "section_title": "Available data from published observational studies, case series and case reports over several decades do not suggest an"
        }
    },
    {
        "page_number": 9,
        "section_number": 15,
        "content": "increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant",
        "metadata": {
            "section_title": "increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant"
        }
    },
    {
        "page_number": 9,
        "section_number": 16,
        "content": "women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying",
        "metadata": {
            "section_title": "women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying"
        }
    },
    {
        "page_number": 9,
        "section_number": 17,
        "content": "maternal disease and maternal use of concomitant medications.",
        "metadata": {
            "section_title": "maternal disease and maternal use of concomitant medications."
        }
    },
    {
        "page_number": 9,
        "section_number": 18,
        "content": "Animal Data",
        "metadata": {
            "section_title": "Animal Data"
        }
    },
    {
        "page_number": 9,
        "section_number": 19,
        "content": "Reproductive and developmental toxicology studies have not been conducted using IV  administration of azithromycin to",
        "metadata": {
            "section_title": "Reproductive and developmental toxicology studies have not been conducted using IV  administration of azithromycin to"
        }
    },
    {
        "page_number": 9,
        "section_number": 20,
        "content": "animals. Azithromycin administered during the period of or ganogenesis did not cause fetal malformations in rats and mice at",
        "metadata": {
            "section_title": "animals. Azithromycin administered during the period of or ganogenesis did not cause fetal malformations in rats and mice at"
        }
    },
    {
        "page_number": 9,
        "section_number": 21,
        "content": "oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 4 (rats)",
        "metadata": {
            "section_title": "oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 4 (rats)"
        }
    },
    {
        "page_number": 9,
        "section_number": 22,
        "content": "and 2 (mice) times an adult human daily dose of 500 mg. In rabbits administered azithromycin at oral doses of 10, 20 and 40",
        "metadata": {
            "section_title": "and 2 (mice) times an adult human daily dose of 500 mg. In rabbits administered azithromycin at oral doses of 10, 20 and 40"
        }
    },
    {
        "page_number": 9,
        "section_number": 23,
        "content": "mg/kg/day during or ganogenesis, reduced maternal body weight and food consumption were observed in all groups; no",
        "metadata": {
            "section_title": "mg/kg/day during or ganogenesis, reduced maternal body weight and food consumption were observed in all groups; no"
        }
    },
    {
        "page_number": 9,
        "section_number": 24,
        "content": "evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2 times an adult",
        "metadata": {
            "section_title": "evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2 times an adult"
        }
    },
    {
        "page_number": 9,
        "section_number": 25,
        "content": "human daily dose of 500 mg based on body surface area.",
        "metadata": {
            "section_title": "human daily dose of 500 mg based on body surface area."
        }
    },
    {
        "page_number": 9,
        "section_number": 26,
        "content": "In a pre- and postnatal development study , azithromycin was administered orally to pregnant rats from day 6 of pregnancy until",
        "metadata": {
            "section_title": "In a pre- and postnatal development study , azithromycin was administered orally to pregnant rats from day 6 of pregnancy until"
        }
    },
    {
        "page_number": 9,
        "section_number": 27,
        "content": "weaning at doses of 50 or 200 mg/kg/day . Maternal toxicity (reduced food consumption and body weight gain; increased stress",
        "metadata": {
            "section_title": "weaning at doses of 50 or 200 mg/kg/day . Maternal toxicity (reduced food consumption and body weight gain; increased stress"
        }
    },
    {
        "page_number": 9,
        "section_number": 28,
        "content": "at parturition) was observed at the higher dose. Ef fects in the of fspring were noted at 200 mg/kg/day during the postnatal",
        "metadata": {
            "section_title": "at parturition) was observed at the higher dose. Ef fects in the of fspring were noted at 200 mg/kg/day during the postnatal"
        }
    },
    {
        "page_number": 9,
        "section_number": 29,
        "content": "development period (decreased viability , delayed developmental landmarks). These ef fects were not observed in a pre- and",
        "metadata": {
            "section_title": "development period (decreased viability , delayed developmental landmarks). These ef fects were not observed in a pre- and"
        }
    },
    {
        "page_number": 9,
        "section_number": 30,
        "content": "postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until",
        "metadata": {
            "section_title": "postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until"
        }
    },
    {
        "page_number": 9,
        "section_number": 31,
        "content": "weaning.",
        "metadata": {
            "section_title": "weaning."
        }
    },
    {
        "page_number": 9,
        "section_number": 32,
        "content": "8.2 Lactation",
        "metadata": {
            "section_title": "8.2 Lactation"
        }
    },
    {
        "page_number": 9,
        "section_number": 33,
        "content": "Risk Summary",
        "metadata": {
            "section_title": "Risk Summary"
        }
    },
    {
        "page_number": 9,
        "section_number": 34,
        "content": "Azithromycin is present in human milk (see Data ). Non-serious adverse reactions have been reported in breastfed infants after",
        "metadata": {
            "section_title": "Azithromycin is present in human milk (see Data ). Non-serious adverse reactions have been reported in breastfed infants after"
        }
    },
    {
        "page_number": 9,
        "section_number": 35,
        "content": "maternal administration of azithromycin (see Clinical Considerations ). There are no available data on the ef fects of",
        "metadata": {
            "section_title": "maternal administration of azithromycin (see Clinical Considerations ). There are no available data on the ef fects of"
        }
    },
    {
        "page_number": 9,
        "section_number": 36,
        "content": "azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the",
        "metadata": {
            "section_title": "azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the"
        }
    },
    {
        "page_number": 9,
        "section_number": 37,
        "content": "mother's clinical need for azithromycin and any potential adverse ef fects on the breastfed infant from azithromycin or from the",
        "metadata": {
            "section_title": "mother's clinical need for azithromycin and any potential adverse ef fects on the breastfed infant from azithromycin or from the"
        }
    },
    {
        "page_number": 9,
        "section_number": 38,
        "content": "underlying maternal condition.",
        "metadata": {
            "section_title": "underlying maternal condition."
        }
    },
    {
        "page_number": 9,
        "section_number": 39,
        "content": "Clinical Considerations",
        "metadata": {
            "section_title": "Clinical Considerations"
        }
    },
    {
        "page_number": 9,
        "section_number": 40,
        "content": "Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.",
        "metadata": {
            "section_title": "Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash."
        }
    },
    {
        "page_number": 9,
        "section_number": 41,
        "content": "Data",
        "metadata": {
            "section_title": "Data"
        }
    },
    {
        "page_number": 9,
        "section_number": 42,
        "content": "Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral dose of azithromycin",
        "metadata": {
            "section_title": "Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral dose of azithromycin"
        }
    },
    {
        "page_number": 9,
        "section_number": 43,
        "content": "during labor . Breastmilk samples collected on days 3 and 6 postpartum as well as 2 and 4 weeks postpartum revealed the",
        "metadata": {
            "section_title": "during labor . Breastmilk samples collected on days 3 and 6 postpartum as well as 2 and 4 weeks postpartum revealed the"
        }
    },
    {
        "page_number": 9,
        "section_number": 44,
        "content": "presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study , a single dose of azithromycin 500 mg was",
        "metadata": {
            "section_title": "presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study , a single dose of azithromycin 500 mg was"
        }
    },
    {
        "page_number": 9,
        "section_number": 45,
        "content": "administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained",
        "metadata": {
            "section_title": "administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained"
        }
    },
    {
        "page_number": 9,
        "section_number": 46,
        "content": "between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.",
        "metadata": {
            "section_title": "between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours."
        }
    },
    {
        "page_number": 9,
        "section_number": 47,
        "content": "8.4 Pediatric Use",
        "metadata": {
            "section_title": "8.4 Pediatric Use"
        }
    },
    {
        "page_number": 9,
        "section_number": 48,
        "content": "Safety and ef fectiveness of azithromycin for injection in children or adolescents under 16 years have not been established. In",
        "metadata": {
            "section_title": "Safety and ef fectiveness of azithromycin for injection in children or adolescents under 16 years have not been established. In"
        }
    },
    {
        "page_number": 9,
        "section_number": 49,
        "content": "controlled clinical studies, azithromycin has been administered to pediatric patients (age 6 months to 16 years) by the oral",
        "metadata": {
            "section_title": "controlled clinical studies, azithromycin has been administered to pediatric patients (age 6 months to 16 years) by the oral"
        }
    },
    {
        "page_number": 9,
        "section_number": 50,
        "content": "route. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, [ see",
        "metadata": {
            "section_title": "route. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, [ see"
        }
    },
    {
        "page_number": 10,
        "section_number": 1,
        "content": "Indications and Usage (1)  and Dosage and Administration (2) ] of the prescribing information for Azithromycin for oral",
        "metadata": {
            "section_title": "Indications and Usage (1)  and Dosage and Administration (2) ] of the prescribing information for Azithromycin for oral"
        }
    },
    {
        "page_number": 10,
        "section_number": 2,
        "content": "suspension 100 mg/5 mL  and 200 mg/5 mL  bottles.",
        "metadata": {
            "section_title": "suspension 100 mg/5 mL  and 200 mg/5 mL  bottles."
        }
    },
    {
        "page_number": 10,
        "section_number": 3,
        "content": "8.5 Geriatric Use",
        "metadata": {
            "section_title": "8.5 Geriatric Use"
        }
    },
    {
        "page_number": 10,
        "section_number": 4,
        "content": "Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of",
        "metadata": {
            "section_title": "Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of"
        }
    },
    {
        "page_number": 10,
        "section_number": 5,
        "content": "azithromycin following oral administration in older volunteers (65-85 years old) were similar to those in younger volunteers",
        "metadata": {
            "section_title": "azithromycin following oral administration in older volunteers (65-85 years old) were similar to those in younger volunteers"
        }
    },
    {
        "page_number": 10,
        "section_number": 6,
        "content": "(18-40 years old) for the 5-day therapeutic regimen.",
        "metadata": {
            "section_title": "(18-40 years old) for the 5-day therapeutic regimen."
        }
    },
    {
        "page_number": 10,
        "section_number": 7,
        "content": "In multiple-dose clinical trials of intravenous azithromycin in the treatment of community-acquired pneumonia, 45% of",
        "metadata": {
            "section_title": "In multiple-dose clinical trials of intravenous azithromycin in the treatment of community-acquired pneumonia, 45% of"
        }
    },
    {
        "page_number": 10,
        "section_number": 8,
        "content": "patients (188/414) were at least 65 years of age and 22% of patients (91/414) were at least 75 years of age. No overall",
        "metadata": {
            "section_title": "patients (188/414) were at least 65 years of age and 22% of patients (91/414) were at least 75 years of age. No overall"
        }
    },
    {
        "page_number": 10,
        "section_number": 9,
        "content": "differences in safety were observed between these subjects and younger subjects in terms of adverse reactions, laboratory",
        "metadata": {
            "section_title": "differences in safety were observed between these subjects and younger subjects in terms of adverse reactions, laboratory"
        }
    },
    {
        "page_number": 10,
        "section_number": 10,
        "content": "abnormalities, and discontinuations. Similar decreases in clinical response were noted in azithromycin- and comparator -treated",
        "metadata": {
            "section_title": "abnormalities, and discontinuations. Similar decreases in clinical response were noted in azithromycin- and comparator -treated"
        }
    },
    {
        "page_number": 10,
        "section_number": 11,
        "content": "patients with increasing age.",
        "metadata": {
            "section_title": "patients with increasing age."
        }
    },
    {
        "page_number": 10,
        "section_number": 12,
        "content": "Azithromycin for Injection contains 1 14 mg (4.96 mEq) of sodium per vial. At the usual recommended doses, patients would",
        "metadata": {
            "section_title": "Azithromycin for Injection contains 1 14 mg (4.96 mEq) of sodium per vial. At the usual recommended doses, patients would"
        }
    },
    {
        "page_number": 10,
        "section_number": 13,
        "content": "receive 1 14 mg (4.96 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. The",
        "metadata": {
            "section_title": "receive 1 14 mg (4.96 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. The"
        }
    },
    {
        "page_number": 10,
        "section_number": 14,
        "content": "total sodium content from dietary and non-dietary sources may be clinically important with regard to such diseases as",
        "metadata": {
            "section_title": "total sodium content from dietary and non-dietary sources may be clinically important with regard to such diseases as"
        }
    },
    {
        "page_number": 10,
        "section_number": 15,
        "content": "congestive heart failure.",
        "metadata": {
            "section_title": "congestive heart failure."
        }
    },
    {
        "page_number": 10,
        "section_number": 16,
        "content": "Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients [ see",
        "metadata": {
            "section_title": "Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients [ see"
        }
    },
    {
        "page_number": 10,
        "section_number": 17,
        "content": "Warnings and Pr ecautions (5.4) ].",
        "metadata": {
            "section_title": "Warnings and Pr ecautions (5.4) ]."
        }
    },
    {
        "page_number": 10,
        "section_number": 18,
        "content": "10 OVERDOSAGE",
        "metadata": {
            "section_title": "10 OVERDOSAGE"
        }
    },
    {
        "page_number": 10,
        "section_number": 19,
        "content": "Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses particularly",
        "metadata": {
            "section_title": "Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses particularly"
        }
    },
    {
        "page_number": 10,
        "section_number": 20,
        "content": "nausea, diarrhea, and vomiting. In the event of overdosage, general symptomatic and supportive measures are indicated as",
        "metadata": {
            "section_title": "nausea, diarrhea, and vomiting. In the event of overdosage, general symptomatic and supportive measures are indicated as"
        }
    },
    {
        "page_number": 10,
        "section_number": 21,
        "content": "required.",
        "metadata": {
            "section_title": "required."
        }
    },
    {
        "page_number": 10,
        "section_number": 22,
        "content": "11 DESCRIPTION",
        "metadata": {
            "section_title": "11 DESCRIPTION"
        }
    },
    {
        "page_number": 10,
        "section_number": 23,
        "content": "Azithromycin for Injection, USP  contains the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics,",
        "metadata": {
            "section_title": "Azithromycin for Injection, USP  contains the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics,"
        }
    },
    {
        "page_number": 10,
        "section_number": 24,
        "content": "for intravenous injection. Azithromycin has the chemical name ( 2R,3S,4R,5R,8R,10R,1 1R,12S,13S,14R )-13-[(2,6-dideoxy-3- C-",
        "metadata": {
            "section_title": "for intravenous injection. Azithromycin has the chemical name ( 2R,3S,4R,5R,8R,10R,1 1R,12S,13S,14R )-13-[(2,6-dideoxy-3- C-"
        }
    },
    {
        "page_number": 10,
        "section_number": 25,
        "content": "methyl-3- O-methyl-α- L-ribo -hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-hepta-methyl-1 1-[[3,4,6-",
        "metadata": {
            "section_title": "methyl-3- O-methyl-α- L-ribo -hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-hepta-methyl-1 1-[[3,4,6-"
        }
    },
    {
        "page_number": 10,
        "section_number": 26,
        "content": "trideoxy-3-(dimethylamino)-β- D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from",
        "metadata": {
            "section_title": "trideoxy-3-(dimethylamino)-β- D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from"
        }
    },
    {
        "page_number": 10,
        "section_number": 27,
        "content": "erythromycin; however , it dif fers chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into",
        "metadata": {
            "section_title": "erythromycin; however , it dif fers chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into"
        }
    },
    {
        "page_number": 10,
        "section_number": 28,
        "content": "the lactone ring. Its molecular formula is C HNO, and its molecular weight is 749. Azithromycin has the following",
        "metadata": {
            "section_title": "the lactone ring. Its molecular formula is C HNO, and its molecular weight is 749. Azithromycin has the following"
        }
    },
    {
        "page_number": 10,
        "section_number": 29,
        "content": "structural formula:",
        "metadata": {
            "section_title": "structural formula:"
        }
    },
    {
        "page_number": 10,
        "section_number": 30,
        "content": "Azithromycin, as the monohydrate, is a white crystalline powder with a molecular formula of C HNO ∙ HO and a",
        "metadata": {
            "section_title": "Azithromycin, as the monohydrate, is a white crystalline powder with a molecular formula of C HNO ∙ HO and a"
        }
    },
    {
        "page_number": 10,
        "section_number": 31,
        "content": "molecular weight of 767.",
        "metadata": {
            "section_title": "molecular weight of 767."
        }
    },
    {
        "page_number": 10,
        "section_number": 32,
        "content": "Azithromycin for Injection, USP  consists of azithromycin monohydrate and the following inactive ingredients: anhydrous",
        "metadata": {
            "section_title": "Azithromycin for Injection, USP  consists of azithromycin monohydrate and the following inactive ingredients: anhydrous"
        }
    },
    {
        "page_number": 10,
        "section_number": 33,
        "content": "citric acid and sodium hydroxide. Sodium hydroxide is added to adjust the pH. Azithromycin for Injection, USP  is supplied as3872212",
        "metadata": {
            "section_title": "citric acid and sodium hydroxide. Sodium hydroxide is added to adjust the pH. Azithromycin for Injection, USP  is supplied as3872212"
        }
    },
    {
        "page_number": 10,
        "section_number": 34,
        "content": "3872212 2",
        "metadata": {
            "section_title": "3872212 2"
        }
    },
    {
        "page_number": 11,
        "section_number": 1,
        "content": "white to of f-white lyophilized powder in a single-dose vial for intravenous administration. Each vial contains azithromycin",
        "metadata": {
            "section_title": "white to of f-white lyophilized powder in a single-dose vial for intravenous administration. Each vial contains azithromycin"
        }
    },
    {
        "page_number": 11,
        "section_number": 2,
        "content": "monohydrate equivalent to 500 mg azithromycin, 413.6 mg anhydrous citric acid and sodium hydroxide for pH adjustment.",
        "metadata": {
            "section_title": "monohydrate equivalent to 500 mg azithromycin, 413.6 mg anhydrous citric acid and sodium hydroxide for pH adjustment."
        }
    },
    {
        "page_number": 11,
        "section_number": 3,
        "content": "Reconstitution, according to label directions, results in approximately 5 mL  of azithromycin for intravenous injection with",
        "metadata": {
            "section_title": "Reconstitution, according to label directions, results in approximately 5 mL  of azithromycin for intravenous injection with"
        }
    },
    {
        "page_number": 11,
        "section_number": 4,
        "content": "each mL  containing azithromycin monohydrate equivalent to 100 mg of azithromycin, 76.9 mg of anhydrous citric acid and",
        "metadata": {
            "section_title": "each mL  containing azithromycin monohydrate equivalent to 100 mg of azithromycin, 76.9 mg of anhydrous citric acid and"
        }
    },
    {
        "page_number": 11,
        "section_number": 5,
        "content": "sodium hydroxide.",
        "metadata": {
            "section_title": "sodium hydroxide."
        }
    },
    {
        "page_number": 11,
        "section_number": 6,
        "content": "12 CLINICAL  PHARMACOLOGY",
        "metadata": {
            "section_title": "12 CLINICAL  PHARMACOLOGY"
        }
    },
    {
        "page_number": 11,
        "section_number": 7,
        "content": "12.1 Mechanism of Action",
        "metadata": {
            "section_title": "12.1 Mechanism of Action"
        }
    },
    {
        "page_number": 11,
        "section_number": 8,
        "content": "Azithromycin is a macrolide antibacterial drug [ see Micr obiology (12.4) ].",
        "metadata": {
            "section_title": "Azithromycin is a macrolide antibacterial drug [ see Micr obiology (12.4) ]."
        }
    },
    {
        "page_number": 11,
        "section_number": 9,
        "content": "12.2 Pharmacodynamics",
        "metadata": {
            "section_title": "12.2 Pharmacodynamics"
        }
    },
    {
        "page_number": 11,
        "section_number": 10,
        "content": "Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under",
        "metadata": {
            "section_title": "Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under"
        }
    },
    {
        "page_number": 11,
        "section_number": 11,
        "content": "the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens ( S. pneumoniae and S.",
        "metadata": {
            "section_title": "the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens ( S. pneumoniae and S."
        }
    },
    {
        "page_number": 11,
        "section_number": 12,
        "content": "aureus). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has",
        "metadata": {
            "section_title": "aureus). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has"
        }
    },
    {
        "page_number": 11,
        "section_number": 13,
        "content": "not been elucidated in clinical trials with azithromycin.",
        "metadata": {
            "section_title": "not been elucidated in clinical trials with azithromycin."
        }
    },
    {
        "page_number": 11,
        "section_number": 14,
        "content": "Cardiac Electr ophysiology",
        "metadata": {
            "section_title": "Cardiac Electr ophysiology"
        }
    },
    {
        "page_number": 11,
        "section_number": 15,
        "content": "QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 1 16 healthy subjects who received",
        "metadata": {
            "section_title": "QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 1 16 healthy subjects who received"
        }
    },
    {
        "page_number": 11,
        "section_number": 16,
        "content": "either chloroquine (1,000 mg) alone or in combination with oral azithromycin (500 mg, 1,000 mg, and 1,500 mg once daily).",
        "metadata": {
            "section_title": "either chloroquine (1,000 mg) alone or in combination with oral azithromycin (500 mg, 1,000 mg, and 1,500 mg once daily)."
        }
    },
    {
        "page_number": 11,
        "section_number": 17,
        "content": "Co-administration of azithromycin increased the QT c interval in a dose- and concentration- dependent manner . In comparison",
        "metadata": {
            "section_title": "Co-administration of azithromycin increased the QT c interval in a dose- and concentration- dependent manner . In comparison"
        }
    },
    {
        "page_number": 11,
        "section_number": 18,
        "content": "to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QT cF were 5 (10) ms, 7 (12) ms and 9",
        "metadata": {
            "section_title": "to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QT cF were 5 (10) ms, 7 (12) ms and 9"
        }
    },
    {
        "page_number": 11,
        "section_number": 19,
        "content": "(14) ms with the co-administration of 500 mg, 1,000 mg and 1,500 mg azithromycin, respectively .",
        "metadata": {
            "section_title": "(14) ms with the co-administration of 500 mg, 1,000 mg and 1,500 mg azithromycin, respectively ."
        }
    },
    {
        "page_number": 11,
        "section_number": 20,
        "content": "Since the mean C  of azithromycin following a 500 mg IV  dose given over 1 hour is higher than the mean C  of",
        "metadata": {
            "section_title": "Since the mean C  of azithromycin following a 500 mg IV  dose given over 1 hour is higher than the mean C  of"
        }
    },
    {
        "page_number": 11,
        "section_number": 21,
        "content": "azithromycin following the administration of a 1,500 mg oral dose, it is possible that QT c may be prolonged to a greater extent",
        "metadata": {
            "section_title": "azithromycin following the administration of a 1,500 mg oral dose, it is possible that QT c may be prolonged to a greater extent"
        }
    },
    {
        "page_number": 11,
        "section_number": 22,
        "content": "with IV  azithromycin at close proximity to a one hour infusion of 500 mg.",
        "metadata": {
            "section_title": "with IV  azithromycin at close proximity to a one hour infusion of 500 mg."
        }
    },
    {
        "page_number": 11,
        "section_number": 23,
        "content": "12.3 Pharmacokinetics",
        "metadata": {
            "section_title": "12.3 Pharmacokinetics"
        }
    },
    {
        "page_number": 11,
        "section_number": 24,
        "content": "In patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5",
        "metadata": {
            "section_title": "In patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5"
        }
    },
    {
        "page_number": 11,
        "section_number": 25,
        "content": "days of 500-mg azithromycin at a concentration of 2 mg/mL, the mean C  ± S.D. achieved was 3.63 ± 1.60 mcg/mL, while",
        "metadata": {
            "section_title": "days of 500-mg azithromycin at a concentration of 2 mg/mL, the mean C  ± S.D. achieved was 3.63 ± 1.60 mcg/mL, while"
        }
    },
    {
        "page_number": 11,
        "section_number": 26,
        "content": "the 24-hour trough level was 0.20 ± 0.15 mcg/mL, and the AUC  was 9.60 ± 4.80 mcg∙hr/mL.",
        "metadata": {
            "section_title": "the 24-hour trough level was 0.20 ± 0.15 mcg/mL, and the AUC  was 9.60 ± 4.80 mcg∙hr/mL."
        }
    },
    {
        "page_number": 11,
        "section_number": 27,
        "content": "The mean C , 24-hour trough and AUC  values were 1.14 ± 0.14 mcg/mL, 0.18 ± 0.02 mcg/mL, and 8.03 ±0.86",
        "metadata": {
            "section_title": "The mean C , 24-hour trough and AUC  values were 1.14 ± 0.14 mcg/mL, 0.18 ± 0.02 mcg/mL, and 8.03 ±0.86"
        }
    },
    {
        "page_number": 11,
        "section_number": 28,
        "content": "mcg∙hr/mL, respectively , in normal volunteers receiving a 3-hour intravenous infusion of 500 mg azithromycin at a",
        "metadata": {
            "section_title": "mcg∙hr/mL, respectively , in normal volunteers receiving a 3-hour intravenous infusion of 500 mg azithromycin at a"
        }
    },
    {
        "page_number": 11,
        "section_number": 29,
        "content": "concentration of 1 mg/mL. Similar pharmacokinetic values were obtained in patients hospitalized with community-acquired",
        "metadata": {
            "section_title": "concentration of 1 mg/mL. Similar pharmacokinetic values were obtained in patients hospitalized with community-acquired"
        }
    },
    {
        "page_number": 11,
        "section_number": 30,
        "content": "pneumonia who received the same 3-hour dosage regimen for 2-5 days.",
        "metadata": {
            "section_title": "pneumonia who received the same 3-hour dosage regimen for 2-5 days."
        }
    },
    {
        "page_number": 11,
        "section_number": 31,
        "content": "Infusion",
        "metadata": {
            "section_title": "Infusion"
        }
    },
    {
        "page_number": 11,
        "section_number": 32,
        "content": "Concentration,",
        "metadata": {
            "section_title": "Concentration,"
        }
    },
    {
        "page_number": 11,
        "section_number": 33,
        "content": "DurationTime after  starting the infusion (hr)",
        "metadata": {
            "section_title": "DurationTime after  starting the infusion (hr)"
        }
    },
    {
        "page_number": 11,
        "section_number": 34,
        "content": "",
        "metadata": {
            "section_title": " "
        }
    },
    {
        "page_number": 11,
        "section_number": 35,
        "content": "0.5",
        "metadata": {
            "section_title": "0.5 "
        }
    },
    {
        "page_number": 11,
        "section_number": 36,
        "content": "1 2 3 4 6",
        "metadata": {
            "section_title": "1 2 3 4 6 "
        }
    },
    {
        "page_number": 11,
        "section_number": 37,
        "content": "8",
        "metadata": {
            "section_title": "8 "
        }
    },
    {
        "page_number": 11,
        "section_number": 38,
        "content": "12",
        "metadata": {
            "section_title": "12 "
        }
    },
    {
        "page_number": 11,
        "section_number": 39,
        "content": "24",
        "metadata": {
            "section_title": "24"
        }
    },
    {
        "page_number": 11,
        "section_number": 40,
        "content": "2 mg/mL, 1 hr 2.98",
        "metadata": {
            "section_title": "2 mg/mL, 1 hr 2.98"
        }
    },
    {
        "page_number": 11,
        "section_number": 41,
        "content": "±1.12 3.63 ±1.73 0.60 ±0.31 0.40 ±0.23 0.33 ±0.16 0.26 ±0.14 0.27 ±0.15 0.20 ±0.12 0.20 ±0.15",
        "metadata": {
            "section_title": "±1.12 3.63 ±1.73 0.60 ±0.31 0.40 ±0.23 0.33 ±0.16 0.26 ±0.14 0.27 ±0.15 0.20 ±0.12 0.20 ±0.15"
        }
    },
    {
        "page_number": 11,
        "section_number": 42,
        "content": "1 mg/mL, 3 hr 0.91",
        "metadata": {
            "section_title": "1 mg/mL, 3 hr 0.91"
        }
    },
    {
        "page_number": 11,
        "section_number": 43,
        "content": "±0.13 1.02 ±0.1 11.14 ±0.13 1.13 ±0.16 0.32 ±0.05 0.28 ±0.04 0.27 ±0.03 0.22 ±0.02 0.18 ±0.02",
        "metadata": {
            "section_title": "±0.13 1.02 ±0.1 11.14 ±0.13 1.13 ±0.16 0.32 ±0.05 0.28 ±0.04 0.27 ±0.03 0.22 ±0.02 0.18 ±0.02"
        }
    },
    {
        "page_number": 11,
        "section_number": 44,
        "content": "500 mg (2 mg/mL) for 2-5 days in community-acquired pneumonia patients.",
        "metadata": {
            "section_title": " 500 mg (2 mg/mL) for 2-5 days in community-acquired pneumonia patients."
        }
    },
    {
        "page_number": 11,
        "section_number": 45,
        "content": "500 mg (1 mg/mL) for 5 days in healthy subjects.",
        "metadata": {
            "section_title": " 500 mg (1 mg/mL) for 5 days in healthy subjects."
        }
    },
    {
        "page_number": 11,
        "section_number": 46,
        "content": "Comparison of the plasma pharmacokinetic parameters following the 1st and 5th daily doses of 500 mg intravenous",
        "metadata": {
            "section_title": "Comparison of the plasma pharmacokinetic parameters following the 1st and 5th daily doses of 500 mg intravenous"
        }
    },
    {
        "page_number": 11,
        "section_number": 47,
        "content": "azithromycin showed only an 8% increase in C  but a 61% increase in AUC  reflecting a threefold rise in C  trough levels.",
        "metadata": {
            "section_title": "azithromycin showed only an 8% increase in C  but a 61% increase in AUC  reflecting a threefold rise in C  trough levels."
        }
    },
    {
        "page_number": 11,
        "section_number": 48,
        "content": "Following single-oral doses of 500 mg azithromycin (two 250 mg capsules) to 12 healthy volunteers, C , trough level, and",
        "metadata": {
            "section_title": "Following single-oral doses of 500 mg azithromycin (two 250 mg capsules) to 12 healthy volunteers, C , trough level, and"
        }
    },
    {
        "page_number": 11,
        "section_number": 49,
        "content": "AUC  were reported to be 0.41 mcg/mL, 0.05 mcg/mL, and 2.6 mcg∙h/mL, respectively . These oral values are approximately",
        "metadata": {
            "section_title": "AUC  were reported to be 0.41 mcg/mL, 0.05 mcg/mL, and 2.6 mcg∙h/mL, respectively . These oral values are approximately"
        }
    },
    {
        "page_number": 11,
        "section_number": 50,
        "content": "38%, 83%, and 52% of the values observed following a single 500-mg I.V . 3-hour infusion (C : 1.08 mcg/mL, trough: 0.06",
        "metadata": {
            "section_title": "38%, 83%, and 52% of the values observed following a single 500-mg I.V . 3-hour infusion (C : 1.08 mcg/mL, trough: 0.06"
        }
    },
    {
        "page_number": 11,
        "section_number": 51,
        "content": "mcg/mL, and AUC : 5 mcg∙h/mL). Thus, plasma concentrations are higher following the intravenous regimen throughout the",
        "metadata": {
            "section_title": "mcg/mL, and AUC : 5 mcg∙h/mL). Thus, plasma concentrations are higher following the intravenous regimen throughout the"
        }
    },
    {
        "page_number": 11,
        "section_number": 52,
        "content": "24-hour interval.max max",
        "metadata": {
            "section_title": "24-hour interval.max max"
        }
    },
    {
        "page_number": 11,
        "section_number": 53,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 11,
        "section_number": 54,
        "content": "24",
        "metadata": {
            "section_title": "24"
        }
    },
    {
        "page_number": 11,
        "section_number": 55,
        "content": "max 24",
        "metadata": {
            "section_title": "max 24"
        }
    },
    {
        "page_number": 11,
        "section_number": 56,
        "content": "a",
        "metadata": {
            "section_title": "a"
        }
    },
    {
        "page_number": 11,
        "section_number": 57,
        "content": "ba",
        "metadata": {
            "section_title": "ba"
        }
    },
    {
        "page_number": 11,
        "section_number": 58,
        "content": "b",
        "metadata": {
            "section_title": "b"
        }
    },
    {
        "page_number": 11,
        "section_number": 59,
        "content": "max 24 24",
        "metadata": {
            "section_title": "max 24 24"
        }
    },
    {
        "page_number": 11,
        "section_number": 60,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 11,
        "section_number": 61,
        "content": "24",
        "metadata": {
            "section_title": "24"
        }
    },
    {
        "page_number": 11,
        "section_number": 62,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 11,
        "section_number": 63,
        "content": "24",
        "metadata": {
            "section_title": "24"
        }
    },
    {
        "page_number": 12,
        "section_number": 1,
        "content": "Distribution",
        "metadata": {
            "section_title": "Distribution"
        }
    },
    {
        "page_number": 12,
        "section_number": 2,
        "content": "The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing",
        "metadata": {
            "section_title": "The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing"
        }
    },
    {
        "page_number": 12,
        "section_number": 3,
        "content": "from 51% at 0.02 mcg/mL  to 7% at 2 mcg/mL.",
        "metadata": {
            "section_title": "from 51% at 0.02 mcg/mL  to 7% at 2 mcg/mL."
        }
    },
    {
        "page_number": 12,
        "section_number": 4,
        "content": "Tissue concentrations have not been obtained following intravenous infusions of azithromycin, but following oral",
        "metadata": {
            "section_title": "Tissue concentrations have not been obtained following intravenous infusions of azithromycin, but following oral"
        }
    },
    {
        "page_number": 12,
        "section_number": 5,
        "content": "administration in humans azithromycin has been shown to penetrate into tissues, including skin, lung, tonsil, and cervix.",
        "metadata": {
            "section_title": "administration in humans azithromycin has been shown to penetrate into tissues, including skin, lung, tonsil, and cervix."
        }
    },
    {
        "page_number": 12,
        "section_number": 6,
        "content": "Tissue levels were determined following a single oral dose of 500-mg azithromycin in 7 gynecological patients. Approximately",
        "metadata": {
            "section_title": "Tissue levels were determined following a single oral dose of 500-mg azithromycin in 7 gynecological patients. Approximately"
        }
    },
    {
        "page_number": 12,
        "section_number": 7,
        "content": "17 hours after dosing, azithromycin concentrations were 2.7 mcg/g in ovarian tissue, 3.5 mcg/g in uterine tissue, and 3.3 mcg/g",
        "metadata": {
            "section_title": "17 hours after dosing, azithromycin concentrations were 2.7 mcg/g in ovarian tissue, 3.5 mcg/g in uterine tissue, and 3.3 mcg/g"
        }
    },
    {
        "page_number": 12,
        "section_number": 8,
        "content": "in salpinx. Following a regimen of 500 mg on the first day followed by 250 mg daily for 4 days, concentrations in the",
        "metadata": {
            "section_title": "in salpinx. Following a regimen of 500 mg on the first day followed by 250 mg daily for 4 days, concentrations in the"
        }
    },
    {
        "page_number": 12,
        "section_number": 9,
        "content": "cerebrospinal fluid were less than 0.01 mcg/mL  in the presence of non-inflamed meninges.",
        "metadata": {
            "section_title": "cerebrospinal fluid were less than 0.01 mcg/mL  in the presence of non-inflamed meninges."
        }
    },
    {
        "page_number": 12,
        "section_number": 10,
        "content": "Metabolism",
        "metadata": {
            "section_title": "Metabolism"
        }
    },
    {
        "page_number": 12,
        "section_number": 11,
        "content": "In vitr o and in vivo studies to assess the metabolism of azithromycin have not been performed.",
        "metadata": {
            "section_title": "In vitr o and in vivo studies to assess the metabolism of azithromycin have not been performed."
        }
    },
    {
        "page_number": 12,
        "section_number": 12,
        "content": "Elimination",
        "metadata": {
            "section_title": "Elimination"
        }
    },
    {
        "page_number": 12,
        "section_number": 13,
        "content": "Plasma concentrations of azithromycin following single 500-mg oral and IV  doses declined in a polyphasic pattern with a",
        "metadata": {
            "section_title": "Plasma concentrations of azithromycin following single 500-mg oral and IV  doses declined in a polyphasic pattern with a"
        }
    },
    {
        "page_number": 12,
        "section_number": 14,
        "content": "mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-",
        "metadata": {
            "section_title": "mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-"
        }
    },
    {
        "page_number": 12,
        "section_number": 15,
        "content": "life is thought to be due to extensive uptake and subsequent release of drug from tissues.",
        "metadata": {
            "section_title": "life is thought to be due to extensive uptake and subsequent release of drug from tissues."
        }
    },
    {
        "page_number": 12,
        "section_number": 16,
        "content": "In a multiple-dose study in 12 normal volunteers utilizing a 500-mg (1 mg/mL) one-hour intravenous-dosage regimen for five",
        "metadata": {
            "section_title": "In a multiple-dose study in 12 normal volunteers utilizing a 500-mg (1 mg/mL) one-hour intravenous-dosage regimen for five"
        }
    },
    {
        "page_number": 12,
        "section_number": 17,
        "content": "days, the amount of administered azithromycin dose excreted in urine in 24 hours was about 1 1% after the 1st dose and 14%",
        "metadata": {
            "section_title": "days, the amount of administered azithromycin dose excreted in urine in 24 hours was about 1 1% after the 1st dose and 14%"
        }
    },
    {
        "page_number": 12,
        "section_number": 18,
        "content": "after the 5 dose. These values are greater than the reported 6% excreted unchanged in urine after oral administration of",
        "metadata": {
            "section_title": "after the 5 dose. These values are greater than the reported 6% excreted unchanged in urine after oral administration of"
        }
    },
    {
        "page_number": 12,
        "section_number": 19,
        "content": "azithromycin. Biliary excretion is a major route of elimination for unchanged drug, following oral administration.",
        "metadata": {
            "section_title": "azithromycin. Biliary excretion is a major route of elimination for unchanged drug, following oral administration."
        }
    },
    {
        "page_number": 12,
        "section_number": 20,
        "content": "Specific Populations",
        "metadata": {
            "section_title": "Specific Populations"
        }
    },
    {
        "page_number": 12,
        "section_number": 21,
        "content": "Patients with Renal Impairment",
        "metadata": {
            "section_title": "Patients with Renal Impairment"
        }
    },
    {
        "page_number": 12,
        "section_number": 22,
        "content": "Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of renal",
        "metadata": {
            "section_title": "Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of renal"
        }
    },
    {
        "page_number": 12,
        "section_number": 23,
        "content": "impairment. Following the oral administration of a single 1,000-mg dose of azithromycin, mean C  and AUC  increased",
        "metadata": {
            "section_title": "impairment. Following the oral administration of a single 1,000-mg dose of azithromycin, mean C  and AUC  increased"
        }
    },
    {
        "page_number": 12,
        "section_number": 24,
        "content": "by 5.1% and 4.2%, respectively in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to",
        "metadata": {
            "section_title": "by 5.1% and 4.2%, respectively in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to"
        }
    },
    {
        "page_number": 12,
        "section_number": 25,
        "content": "subjects with normal renal function (GFR >80 mL/min). The mean C  and AUC  increased 61% and 35%, respectively",
        "metadata": {
            "section_title": "subjects with normal renal function (GFR >80 mL/min). The mean C  and AUC  increased 61% and 35%, respectively"
        }
    },
    {
        "page_number": 12,
        "section_number": 26,
        "content": "in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal function",
        "metadata": {
            "section_title": "in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal function"
        }
    },
    {
        "page_number": 12,
        "section_number": 27,
        "content": "(GFR >80 mL/min).",
        "metadata": {
            "section_title": "(GFR >80 mL/min)."
        }
    },
    {
        "page_number": 12,
        "section_number": 28,
        "content": "Patients with Hepatic Impairment",
        "metadata": {
            "section_title": "Patients with Hepatic Impairment"
        }
    },
    {
        "page_number": 12,
        "section_number": 29,
        "content": "The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established.",
        "metadata": {
            "section_title": "The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established."
        }
    },
    {
        "page_number": 12,
        "section_number": 30,
        "content": "Male and Female Patients",
        "metadata": {
            "section_title": "Male and Female Patients"
        }
    },
    {
        "page_number": 12,
        "section_number": 31,
        "content": "There are no significant dif ferences in the disposition of azithromycin between male and female subjects. No dosage",
        "metadata": {
            "section_title": "There are no significant dif ferences in the disposition of azithromycin between male and female subjects. No dosage"
        }
    },
    {
        "page_number": 12,
        "section_number": 32,
        "content": "adjustment is recommended based on gender .",
        "metadata": {
            "section_title": "adjustment is recommended based on gender ."
        }
    },
    {
        "page_number": 12,
        "section_number": 33,
        "content": "Geriatric Patients",
        "metadata": {
            "section_title": "Geriatric Patients"
        }
    },
    {
        "page_number": 12,
        "section_number": 34,
        "content": "Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of",
        "metadata": {
            "section_title": "Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of"
        }
    },
    {
        "page_number": 12,
        "section_number": 35,
        "content": "azithromycin following oral administration in older volunteers (65-85 years old) were similar to those in younger volunteers",
        "metadata": {
            "section_title": "azithromycin following oral administration in older volunteers (65-85 years old) were similar to those in younger volunteers"
        }
    },
    {
        "page_number": 12,
        "section_number": 36,
        "content": "(18-40 years old) for the 5-day therapeutic regimen [ see Geriatric Use (8.5) ].",
        "metadata": {
            "section_title": "(18-40 years old) for the 5-day therapeutic regimen [ see Geriatric Use (8.5) ]."
        }
    },
    {
        "page_number": 12,
        "section_number": 37,
        "content": "Pediatric Patients",
        "metadata": {
            "section_title": "Pediatric Patients"
        }
    },
    {
        "page_number": 12,
        "section_number": 38,
        "content": "Pharmacokinetic studies with intravenous azithromycin have not been performed in children.",
        "metadata": {
            "section_title": "Pharmacokinetic studies with intravenous azithromycin have not been performed in children."
        }
    },
    {
        "page_number": 12,
        "section_number": 39,
        "content": "Drug Interaction Studies",
        "metadata": {
            "section_title": "Drug Interaction Studies"
        }
    },
    {
        "page_number": 12,
        "section_number": 40,
        "content": "Drug interaction studies were performed with oral azithromycin and other drugs likely to be co-administered. The ef fects of",
        "metadata": {
            "section_title": "Drug interaction studies were performed with oral azithromycin and other drugs likely to be co-administered. The ef fects of"
        }
    },
    {
        "page_number": 12,
        "section_number": 41,
        "content": "co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1  and the ef fects of other drugs",
        "metadata": {
            "section_title": "co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1  and the ef fects of other drugs"
        }
    },
    {
        "page_number": 12,
        "section_number": 42,
        "content": "on the pharmacokinetics of azithromycin are shown in Table 2 .",
        "metadata": {
            "section_title": "on the pharmacokinetics of azithromycin are shown in Table 2 ."
        }
    },
    {
        "page_number": 12,
        "section_number": 43,
        "content": "Co-administration of azithromycin at therapeutic doses had a modest ef fect on the pharmacokinetics of the drugs listed in Table",
        "metadata": {
            "section_title": "Co-administration of azithromycin at therapeutic doses had a modest ef fect on the pharmacokinetics of the drugs listed in Table"
        }
    },
    {
        "page_number": 12,
        "section_number": 44,
        "content": "1. No dosage adjustment of drugs listed in Table 1  is recommended when co-administered with azithromycin.",
        "metadata": {
            "section_title": "1. No dosage adjustment of drugs listed in Table 1  is recommended when co-administered with azithromycin."
        }
    },
    {
        "page_number": 12,
        "section_number": 45,
        "content": "Co-administration of azithromycin with efavirenz or fluconazole had a modest ef fect on the pharmacokinetics of azithromycin.",
        "metadata": {
            "section_title": "Co-administration of azithromycin with efavirenz or fluconazole had a modest ef fect on the pharmacokinetics of azithromycin."
        }
    },
    {
        "page_number": 12,
        "section_number": 46,
        "content": "Nelfinavir significantly increased the C  and AUC of azithromycin. No dosage adjustment of azithromycin is recommended",
        "metadata": {
            "section_title": "Nelfinavir significantly increased the C  and AUC of azithromycin. No dosage adjustment of azithromycin is recommended"
        }
    },
    {
        "page_number": 12,
        "section_number": 47,
        "content": "when administered with drugs listed in Table 2  [see Drug Interactions (7.3) ].th",
        "metadata": {
            "section_title": "when administered with drugs listed in Table 2  [see Drug Interactions (7.3) ].th "
        }
    },
    {
        "page_number": 12,
        "section_number": 48,
        "content": "max 0-120",
        "metadata": {
            "section_title": "max 0-120"
        }
    },
    {
        "page_number": 12,
        "section_number": 49,
        "content": "max 0-120",
        "metadata": {
            "section_title": "max 0-120"
        }
    },
    {
        "page_number": 12,
        "section_number": 50,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 13,
        "section_number": 1,
        "content": "Table 1. Drug Interactions: Pharmacokinetic Parameters for  Co-administer ed Drugs in the Pr esence of Azithr omycin",
        "metadata": {
            "section_title": "Table 1. Drug Interactions: Pharmacokinetic Parameters for  Co-administer ed Drugs in the Pr esence of Azithr omycin"
        }
    },
    {
        "page_number": 13,
        "section_number": 2,
        "content": "Co-administer ed",
        "metadata": {
            "section_title": "Co-administer ed"
        }
    },
    {
        "page_number": 13,
        "section_number": 3,
        "content": "DrugDose of Co-",
        "metadata": {
            "section_title": "DrugDose of Co-"
        }
    },
    {
        "page_number": 13,
        "section_number": 4,
        "content": "administer ed Drug Dose of Azithr omycin nRatio (with/without azithr omycin) of Co-",
        "metadata": {
            "section_title": "administer ed Drug Dose of Azithr omycin nRatio (with/without azithr omycin) of Co-"
        }
    },
    {
        "page_number": 13,
        "section_number": 5,
        "content": "administer ed Drug Pharmacokinetic",
        "metadata": {
            "section_title": "administer ed Drug Pharmacokinetic"
        }
    },
    {
        "page_number": 13,
        "section_number": 6,
        "content": "Parameters (90% CI); No Effect = 1",
        "metadata": {
            "section_title": "Parameters (90% CI); No Effect = 1"
        }
    },
    {
        "page_number": 13,
        "section_number": 7,
        "content": "Mean C Mean AUC",
        "metadata": {
            "section_title": "Mean C Mean AUC"
        }
    },
    {
        "page_number": 13,
        "section_number": 8,
        "content": "Atorvastatin 10 mg/day for 8 days 500 mg/day orally on",
        "metadata": {
            "section_title": "Atorvastatin 10 mg/day for 8 days 500 mg/day orally on"
        }
    },
    {
        "page_number": 13,
        "section_number": 9,
        "content": "days 6-812 0.83",
        "metadata": {
            "section_title": "days 6-812 0.83"
        }
    },
    {
        "page_number": 13,
        "section_number": 10,
        "content": "(0.63 to 1.08)1.01",
        "metadata": {
            "section_title": "(0.63 to 1.08)1.01"
        }
    },
    {
        "page_number": 13,
        "section_number": 11,
        "content": "(0.81 to 1.25)",
        "metadata": {
            "section_title": "(0.81 to 1.25)"
        }
    },
    {
        "page_number": 13,
        "section_number": 12,
        "content": "Carbamazepine 200 mg/day for 2 days,",
        "metadata": {
            "section_title": "Carbamazepine 200 mg/day for 2 days,"
        }
    },
    {
        "page_number": 13,
        "section_number": 13,
        "content": "then 200 mg twice a day",
        "metadata": {
            "section_title": "then 200 mg twice a day"
        }
    },
    {
        "page_number": 13,
        "section_number": 14,
        "content": "for 18 days500 mg/day orally for",
        "metadata": {
            "section_title": "for 18 days500 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 15,
        "content": "days 16-187 0.97",
        "metadata": {
            "section_title": "days 16-187 0.97"
        }
    },
    {
        "page_number": 13,
        "section_number": 16,
        "content": "(0.88 to 1.06)0.96",
        "metadata": {
            "section_title": "(0.88 to 1.06)0.96"
        }
    },
    {
        "page_number": 13,
        "section_number": 17,
        "content": "(0.88 to 1.06)",
        "metadata": {
            "section_title": "(0.88 to 1.06)"
        }
    },
    {
        "page_number": 13,
        "section_number": 18,
        "content": "Cetirizine 20 mg/day for 1 1 days 500 mg orally on day 7,",
        "metadata": {
            "section_title": "Cetirizine 20 mg/day for 1 1 days 500 mg orally on day 7,"
        }
    },
    {
        "page_number": 13,
        "section_number": 19,
        "content": "then 250 mg/day on days",
        "metadata": {
            "section_title": "then 250 mg/day on days"
        }
    },
    {
        "page_number": 13,
        "section_number": 20,
        "content": "8-1114 1.03",
        "metadata": {
            "section_title": "8-1114 1.03"
        }
    },
    {
        "page_number": 13,
        "section_number": 21,
        "content": "(0.93 to 1.14)1.02",
        "metadata": {
            "section_title": "(0.93 to 1.14)1.02"
        }
    },
    {
        "page_number": 13,
        "section_number": 22,
        "content": "(0.92 to 1.13)",
        "metadata": {
            "section_title": "(0.92 to 1.13)"
        }
    },
    {
        "page_number": 13,
        "section_number": 23,
        "content": "Didanosine 200 mg orally twice a day",
        "metadata": {
            "section_title": "Didanosine 200 mg orally twice a day"
        }
    },
    {
        "page_number": 13,
        "section_number": 24,
        "content": "for 21 days1,200 mg/day orally on",
        "metadata": {
            "section_title": "for 21 days1,200 mg/day orally on"
        }
    },
    {
        "page_number": 13,
        "section_number": 25,
        "content": "days 8-216 1.44",
        "metadata": {
            "section_title": "days 8-216 1.44"
        }
    },
    {
        "page_number": 13,
        "section_number": 26,
        "content": "(0.85 to 2.43)1.14",
        "metadata": {
            "section_title": "(0.85 to 2.43)1.14"
        }
    },
    {
        "page_number": 13,
        "section_number": 27,
        "content": "(0.83 to 1.57)",
        "metadata": {
            "section_title": "(0.83 to 1.57)"
        }
    },
    {
        "page_number": 13,
        "section_number": 28,
        "content": "Efavirenz 400 mg/day for 7 days 600 mg orally on day 7 14 1.04 0.95",
        "metadata": {
            "section_title": "Efavirenz 400 mg/day for 7 days 600 mg orally on day 7 14 1.04 0.95"
        }
    },
    {
        "page_number": 13,
        "section_number": 29,
        "content": "Fluconazole 200 mg orally single dose 1,200 mg orally single",
        "metadata": {
            "section_title": "Fluconazole 200 mg orally single dose 1,200 mg orally single"
        }
    },
    {
        "page_number": 13,
        "section_number": 30,
        "content": "dose18 1.04",
        "metadata": {
            "section_title": "dose18 1.04"
        }
    },
    {
        "page_number": 13,
        "section_number": 31,
        "content": "(0.98 to 1.1 1)1.01",
        "metadata": {
            "section_title": "(0.98 to 1.1 1)1.01"
        }
    },
    {
        "page_number": 13,
        "section_number": 32,
        "content": "(0.97 to 1.05)",
        "metadata": {
            "section_title": "(0.97 to 1.05)"
        }
    },
    {
        "page_number": 13,
        "section_number": 33,
        "content": "Indinavir 800 mg three times a day",
        "metadata": {
            "section_title": "Indinavir 800 mg three times a day"
        }
    },
    {
        "page_number": 13,
        "section_number": 34,
        "content": "for 5 days1,200 mg orally on day 5 18 0.96",
        "metadata": {
            "section_title": "for 5 days1,200 mg orally on day 5 18 0.96"
        }
    },
    {
        "page_number": 13,
        "section_number": 35,
        "content": "(0.86 to 1.08)0.9",
        "metadata": {
            "section_title": "(0.86 to 1.08)0.9"
        }
    },
    {
        "page_number": 13,
        "section_number": 36,
        "content": "(0.81 to 1)",
        "metadata": {
            "section_title": "(0.81 to 1)"
        }
    },
    {
        "page_number": 13,
        "section_number": 37,
        "content": "Midazolam 15 mg orally on day 3 500 mg/day orally for",
        "metadata": {
            "section_title": "Midazolam 15 mg orally on day 3 500 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 38,
        "content": "3 days12 1.27",
        "metadata": {
            "section_title": "3 days12 1.27"
        }
    },
    {
        "page_number": 13,
        "section_number": 39,
        "content": "(0.89 to 1.81)1.26",
        "metadata": {
            "section_title": "(0.89 to 1.81)1.26"
        }
    },
    {
        "page_number": 13,
        "section_number": 40,
        "content": "(1.01 to 1.56)",
        "metadata": {
            "section_title": "(1.01 to 1.56)"
        }
    },
    {
        "page_number": 13,
        "section_number": 41,
        "content": "Nelfinavir 750 mg three times a day",
        "metadata": {
            "section_title": "Nelfinavir 750 mg three times a day"
        }
    },
    {
        "page_number": 13,
        "section_number": 42,
        "content": "for 1 1 days1,200 mg orally on day 9 14 0.9",
        "metadata": {
            "section_title": "for 1 1 days1,200 mg orally on day 9 14 0.9"
        }
    },
    {
        "page_number": 13,
        "section_number": 43,
        "content": "(0.81 to 1.01)0.85",
        "metadata": {
            "section_title": "(0.81 to 1.01)0.85"
        }
    },
    {
        "page_number": 13,
        "section_number": 44,
        "content": "(0.78 to 0.93)",
        "metadata": {
            "section_title": "(0.78 to 0.93)"
        }
    },
    {
        "page_number": 13,
        "section_number": 45,
        "content": "Sildenafil 100 mg on days 1 and 4 500 mg/day orally for",
        "metadata": {
            "section_title": "Sildenafil 100 mg on days 1 and 4 500 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 46,
        "content": "3 days12 1.16",
        "metadata": {
            "section_title": "3 days12 1.16"
        }
    },
    {
        "page_number": 13,
        "section_number": 47,
        "content": "(0.86 to 1.57)0.92",
        "metadata": {
            "section_title": "(0.86 to 1.57)0.92"
        }
    },
    {
        "page_number": 13,
        "section_number": 48,
        "content": "(0.75 to 1.12)",
        "metadata": {
            "section_title": "(0.75 to 1.12)"
        }
    },
    {
        "page_number": 13,
        "section_number": 49,
        "content": "Theophylline 4 mg/kg IV  on days 1, 1 1,",
        "metadata": {
            "section_title": "Theophylline 4 mg/kg IV  on days 1, 1 1,"
        }
    },
    {
        "page_number": 13,
        "section_number": 50,
        "content": "25500 mg orally on day 7,",
        "metadata": {
            "section_title": "25500 mg orally on day 7,"
        }
    },
    {
        "page_number": 13,
        "section_number": 51,
        "content": "250 mg/day on days 8-1 110 1.19",
        "metadata": {
            "section_title": "250 mg/day on days 8-1 110 1.19"
        }
    },
    {
        "page_number": 13,
        "section_number": 52,
        "content": "(1.02 to 1.4)1.02",
        "metadata": {
            "section_title": "(1.02 to 1.4)1.02"
        }
    },
    {
        "page_number": 13,
        "section_number": 53,
        "content": "(0.86 to 1.22)",
        "metadata": {
            "section_title": "(0.86 to 1.22)"
        }
    },
    {
        "page_number": 13,
        "section_number": 54,
        "content": "Theophylline 300 mg orally twice a day",
        "metadata": {
            "section_title": "Theophylline 300 mg orally twice a day"
        }
    },
    {
        "page_number": 13,
        "section_number": 55,
        "content": "for 15 days500 mg orally on day 6,",
        "metadata": {
            "section_title": "for 15 days500 mg orally on day 6,"
        }
    },
    {
        "page_number": 13,
        "section_number": 56,
        "content": "then 250 mg/day on days",
        "metadata": {
            "section_title": "then 250 mg/day on days"
        }
    },
    {
        "page_number": 13,
        "section_number": 57,
        "content": "7-108 1.09",
        "metadata": {
            "section_title": "7-108 1.09"
        }
    },
    {
        "page_number": 13,
        "section_number": 58,
        "content": "(0.92 to 1.29)1.08",
        "metadata": {
            "section_title": "(0.92 to 1.29)1.08"
        }
    },
    {
        "page_number": 13,
        "section_number": 59,
        "content": "(0.89 to 1.31)",
        "metadata": {
            "section_title": "(0.89 to 1.31)"
        }
    },
    {
        "page_number": 13,
        "section_number": 60,
        "content": "Triazolam 0.125 mg on day 2 500 mg orally on day 1,",
        "metadata": {
            "section_title": "Triazolam 0.125 mg on day 2 500 mg orally on day 1,"
        }
    },
    {
        "page_number": 13,
        "section_number": 61,
        "content": "then 250 mg/day on day 212 1.06 1.02",
        "metadata": {
            "section_title": "then 250 mg/day on day 212 1.06 1.02"
        }
    },
    {
        "page_number": 13,
        "section_number": 62,
        "content": "Trimethoprim/",
        "metadata": {
            "section_title": "Trimethoprim/"
        }
    },
    {
        "page_number": 13,
        "section_number": 63,
        "content": "Sulfamethoxazole160 mg/800 mg/day",
        "metadata": {
            "section_title": "Sulfamethoxazole160 mg/800 mg/day"
        }
    },
    {
        "page_number": 13,
        "section_number": 64,
        "content": "orally for 7 days1,200 mg orally on day 7 12 0.85",
        "metadata": {
            "section_title": "orally for 7 days1,200 mg orally on day 7 12 0.85"
        }
    },
    {
        "page_number": 13,
        "section_number": 65,
        "content": "(0.75 to 0.97)/",
        "metadata": {
            "section_title": "(0.75 to 0.97)/"
        }
    },
    {
        "page_number": 13,
        "section_number": 66,
        "content": "0.9",
        "metadata": {
            "section_title": "0.9"
        }
    },
    {
        "page_number": 13,
        "section_number": 67,
        "content": "(0.78 to 1.03)0.87",
        "metadata": {
            "section_title": "(0.78 to 1.03)0.87"
        }
    },
    {
        "page_number": 13,
        "section_number": 68,
        "content": "(0.8 to 0.95)/",
        "metadata": {
            "section_title": "(0.8 to 0.95)/"
        }
    },
    {
        "page_number": 13,
        "section_number": 69,
        "content": "0.96",
        "metadata": {
            "section_title": "0.96"
        }
    },
    {
        "page_number": 13,
        "section_number": 70,
        "content": "(0.88 to 1.03)",
        "metadata": {
            "section_title": "(0.88 to 1.03)"
        }
    },
    {
        "page_number": 13,
        "section_number": 71,
        "content": "Zidovudine 500 mg/day orally for",
        "metadata": {
            "section_title": "Zidovudine 500 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 72,
        "content": "21 days600 mg/day orally for 14",
        "metadata": {
            "section_title": "21 days600 mg/day orally for 14"
        }
    },
    {
        "page_number": 13,
        "section_number": 73,
        "content": "days5 1.12",
        "metadata": {
            "section_title": "days5 1.12"
        }
    },
    {
        "page_number": 13,
        "section_number": 74,
        "content": "(0.42 to 3.02)0.94",
        "metadata": {
            "section_title": "(0.42 to 3.02)0.94"
        }
    },
    {
        "page_number": 13,
        "section_number": 75,
        "content": "(0.52 to 1.7)",
        "metadata": {
            "section_title": "(0.52 to 1.7)"
        }
    },
    {
        "page_number": 13,
        "section_number": 76,
        "content": "Zidovudine 500 mg/day orally for",
        "metadata": {
            "section_title": "Zidovudine 500 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 77,
        "content": "21 days1,200 mg/day orally for",
        "metadata": {
            "section_title": "21 days1,200 mg/day orally for"
        }
    },
    {
        "page_number": 13,
        "section_number": 78,
        "content": "14 days4 1.31",
        "metadata": {
            "section_title": "14 days4 1.31"
        }
    },
    {
        "page_number": 13,
        "section_number": 79,
        "content": "(0.43 to 3.97)1.3",
        "metadata": {
            "section_title": "(0.43 to 3.97)1.3"
        }
    },
    {
        "page_number": 13,
        "section_number": 80,
        "content": "(0.69 to 2.43)",
        "metadata": {
            "section_title": "(0.69 to 2.43)"
        }
    },
    {
        "page_number": 13,
        "section_number": 81,
        "content": "*",
        "metadata": {
            "section_title": "*"
        }
    },
    {
        "page_number": 13,
        "section_number": 82,
        "content": "Table 2. Drug Interactions: Pharmacokinetic Parameters for  Azithr omycin in the Pr esence of Co-administer ed Drugs",
        "metadata": {
            "section_title": "Table 2. Drug Interactions: Pharmacokinetic Parameters for  Azithr omycin in the Pr esence of Co-administer ed Drugs"
        }
    },
    {
        "page_number": 13,
        "section_number": 83,
        "content": "[see Drug Interactions (7.3) ].",
        "metadata": {
            "section_title": "[see Drug Interactions (7.3) ]."
        }
    },
    {
        "page_number": 13,
        "section_number": 84,
        "content": "Co-administer ed",
        "metadata": {
            "section_title": "Co-administer ed"
        }
    },
    {
        "page_number": 13,
        "section_number": 85,
        "content": "DrugDose of",
        "metadata": {
            "section_title": "DrugDose of"
        }
    },
    {
        "page_number": 13,
        "section_number": 86,
        "content": "Co-administer ed",
        "metadata": {
            "section_title": "Co-administer ed"
        }
    },
    {
        "page_number": 13,
        "section_number": 87,
        "content": "DrugDose of",
        "metadata": {
            "section_title": "DrugDose of"
        }
    },
    {
        "page_number": 13,
        "section_number": 88,
        "content": "Azithr omycin nRatio (with/without co-administer ed drug) of",
        "metadata": {
            "section_title": "Azithr omycin nRatio (with/without co-administer ed drug) of"
        }
    },
    {
        "page_number": 13,
        "section_number": 89,
        "content": "Azithr omycin Pharmacokinetic Parameters (90%",
        "metadata": {
            "section_title": "Azithr omycin Pharmacokinetic Parameters (90%"
        }
    },
    {
        "page_number": 13,
        "section_number": 90,
        "content": "CI); No Effect = 1",
        "metadata": {
            "section_title": "CI); No Effect = 1"
        }
    },
    {
        "page_number": 13,
        "section_number": 91,
        "content": "Mean C Mean AUC",
        "metadata": {
            "section_title": "Mean C Mean AUC"
        }
    },
    {
        "page_number": 13,
        "section_number": 92,
        "content": "Efavirenz400 mg/day for",
        "metadata": {
            "section_title": "Efavirenz400 mg/day for"
        }
    },
    {
        "page_number": 13,
        "section_number": 93,
        "content": "7 days600 mg orally on",
        "metadata": {
            "section_title": "7 days600 mg orally on"
        }
    },
    {
        "page_number": 13,
        "section_number": 94,
        "content": "day 7141.22",
        "metadata": {
            "section_title": "day 7141.22"
        }
    },
    {
        "page_number": 13,
        "section_number": 95,
        "content": "(1.04 to 1.42)0.92",
        "metadata": {
            "section_title": "(1.04 to 1.42)0.92"
        }
    },
    {
        "page_number": 13,
        "section_number": 96,
        "content": "*- 90% Confidence interval not reportedmax",
        "metadata": {
            "section_title": "*- 90% Confidence interval not reportedmax"
        }
    },
    {
        "page_number": 13,
        "section_number": 97,
        "content": "* *",
        "metadata": {
            "section_title": "* *"
        }
    },
    {
        "page_number": 13,
        "section_number": 98,
        "content": "* *",
        "metadata": {
            "section_title": "* *"
        }
    },
    {
        "page_number": 13,
        "section_number": 99,
        "content": "- 90% Confidence interval not reportedmax",
        "metadata": {
            "section_title": "- 90% Confidence interval not reportedmax"
        }
    },
    {
        "page_number": 13,
        "section_number": 100,
        "content": "*",
        "metadata": {
            "section_title": "*"
        }
    },
    {
        "page_number": 14,
        "section_number": 1,
        "content": "Fluconazole200 mg orally single",
        "metadata": {
            "section_title": "Fluconazole200 mg orally single"
        }
    },
    {
        "page_number": 14,
        "section_number": 2,
        "content": "dose1,200 mg orally",
        "metadata": {
            "section_title": "dose1,200 mg orally"
        }
    },
    {
        "page_number": 14,
        "section_number": 3,
        "content": "single dose180.82",
        "metadata": {
            "section_title": "single dose180.82"
        }
    },
    {
        "page_number": 14,
        "section_number": 4,
        "content": "(0.66 to 1.02)1.07",
        "metadata": {
            "section_title": "(0.66 to 1.02)1.07"
        }
    },
    {
        "page_number": 14,
        "section_number": 5,
        "content": "(0.94 to 1.22)",
        "metadata": {
            "section_title": "(0.94 to 1.22)"
        }
    },
    {
        "page_number": 14,
        "section_number": 6,
        "content": "Nelfinavir750 mg three times a",
        "metadata": {
            "section_title": "Nelfinavir750 mg three times a"
        }
    },
    {
        "page_number": 14,
        "section_number": 7,
        "content": "day for 1 1 days1,200 mg orally on",
        "metadata": {
            "section_title": "day for 1 1 days1,200 mg orally on"
        }
    },
    {
        "page_number": 14,
        "section_number": 8,
        "content": "day 9142.36",
        "metadata": {
            "section_title": "day 9142.36"
        }
    },
    {
        "page_number": 14,
        "section_number": 9,
        "content": "(1.77 to 3.15)2.12",
        "metadata": {
            "section_title": "(1.77 to 3.15)2.12"
        }
    },
    {
        "page_number": 14,
        "section_number": 10,
        "content": "(1.80 to 2.5)",
        "metadata": {
            "section_title": "(1.80 to 2.5)"
        }
    },
    {
        "page_number": 14,
        "section_number": 11,
        "content": "*",
        "metadata": {
            "section_title": "*"
        }
    },
    {
        "page_number": 14,
        "section_number": 12,
        "content": "12.4 Micr obiology",
        "metadata": {
            "section_title": "12.4 Micr obiology"
        }
    },
    {
        "page_number": 14,
        "section_number": 13,
        "content": "Mechanism of Action",
        "metadata": {
            "section_title": "Mechanism of Action"
        }
    },
    {
        "page_number": 14,
        "section_number": 14,
        "content": "Azithromycin acts by binding to the 23S rRNA  of the 50S ribosomal subunit of susceptible microor ganisms inhibiting bacterial",
        "metadata": {
            "section_title": "Azithromycin acts by binding to the 23S rRNA  of the 50S ribosomal subunit of susceptible microor ganisms inhibiting bacterial"
        }
    },
    {
        "page_number": 14,
        "section_number": 15,
        "content": "protein synthesis and impeding the assembly of the 50S ribosomal subunit.",
        "metadata": {
            "section_title": "protein synthesis and impeding the assembly of the 50S ribosomal subunit."
        }
    },
    {
        "page_number": 14,
        "section_number": 16,
        "content": "Resistance",
        "metadata": {
            "section_title": "Resistance"
        }
    },
    {
        "page_number": 14,
        "section_number": 17,
        "content": "Azithromycin demonstrates cross-resistance with erythromycin. The most frequently encountered mechanism of resistance to",
        "metadata": {
            "section_title": "Azithromycin demonstrates cross-resistance with erythromycin. The most frequently encountered mechanism of resistance to"
        }
    },
    {
        "page_number": 14,
        "section_number": 18,
        "content": "azithromycin is modification of the 23S rRNA  target, most often by methylation. Ribosomal modifications can determine cross",
        "metadata": {
            "section_title": "azithromycin is modification of the 23S rRNA  target, most often by methylation. Ribosomal modifications can determine cross"
        }
    },
    {
        "page_number": 14,
        "section_number": 19,
        "content": "resistance to other macrolides, lincosamides and streptogramin B (MLS  phenotype).",
        "metadata": {
            "section_title": "resistance to other macrolides, lincosamides and streptogramin B (MLS  phenotype)."
        }
    },
    {
        "page_number": 14,
        "section_number": 20,
        "content": "Antimicr obial Activity",
        "metadata": {
            "section_title": "Antimicr obial Activity"
        }
    },
    {
        "page_number": 14,
        "section_number": 21,
        "content": "Azithromycin has been shown to be active against the following microor ganisms, both in vitr o and in clinical infections. [ see",
        "metadata": {
            "section_title": "Azithromycin has been shown to be active against the following microor ganisms, both in vitr o and in clinical infections. [ see"
        }
    },
    {
        "page_number": 14,
        "section_number": 22,
        "content": "Indications and Usage (1) ]",
        "metadata": {
            "section_title": "Indications and Usage (1) ]"
        }
    },
    {
        "page_number": 14,
        "section_number": 23,
        "content": "Gram-positive Bacteria",
        "metadata": {
            "section_title": "Gram-positive Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 24,
        "content": "Staphylococcus aur eus",
        "metadata": {
            "section_title": "Staphylococcus aur eus"
        }
    },
    {
        "page_number": 14,
        "section_number": 25,
        "content": "Streptococcus pneumoniae",
        "metadata": {
            "section_title": "Streptococcus pneumoniae"
        }
    },
    {
        "page_number": 14,
        "section_number": 26,
        "content": "Gram-negative Bacteria",
        "metadata": {
            "section_title": "Gram-negative Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 27,
        "content": "Haemophilus influenzae",
        "metadata": {
            "section_title": "Haemophilus influenzae"
        }
    },
    {
        "page_number": 14,
        "section_number": 28,
        "content": "Moraxella catarr halis",
        "metadata": {
            "section_title": "Moraxella catarr halis"
        }
    },
    {
        "page_number": 14,
        "section_number": 29,
        "content": "Neisseria gonorr hoeae",
        "metadata": {
            "section_title": "Neisseria gonorr hoeae"
        }
    },
    {
        "page_number": 14,
        "section_number": 30,
        "content": "Legionella pneumophila",
        "metadata": {
            "section_title": "Legionella pneumophila"
        }
    },
    {
        "page_number": 14,
        "section_number": 31,
        "content": "Other  Bacteria",
        "metadata": {
            "section_title": "Other  Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 32,
        "content": "Chlamydophila pneumoniae",
        "metadata": {
            "section_title": "Chlamydophila pneumoniae"
        }
    },
    {
        "page_number": 14,
        "section_number": 33,
        "content": "Chlamydia trachomatis",
        "metadata": {
            "section_title": "Chlamydia trachomatis"
        }
    },
    {
        "page_number": 14,
        "section_number": 34,
        "content": "Mycoplasma hominis",
        "metadata": {
            "section_title": "Mycoplasma hominis"
        }
    },
    {
        "page_number": 14,
        "section_number": 35,
        "content": "Mycoplasma pneumoniae",
        "metadata": {
            "section_title": "Mycoplasma pneumoniae"
        }
    },
    {
        "page_number": 14,
        "section_number": 36,
        "content": "The following in vitr o data are available, but their clinical significance is unknown. At least 90 percent of the following",
        "metadata": {
            "section_title": "The following in vitr o data are available, but their clinical significance is unknown. At least 90 percent of the following"
        }
    },
    {
        "page_number": 14,
        "section_number": 37,
        "content": "bacteria exhibit an in vitr o minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for",
        "metadata": {
            "section_title": "bacteria exhibit an in vitr o minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for"
        }
    },
    {
        "page_number": 14,
        "section_number": 38,
        "content": "azithromycin against isolates of similar genus or or ganism group. However , the ef ficacy of azithromycin in treating clinical",
        "metadata": {
            "section_title": "azithromycin against isolates of similar genus or or ganism group. However , the ef ficacy of azithromycin in treating clinical"
        }
    },
    {
        "page_number": 14,
        "section_number": 39,
        "content": "infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.",
        "metadata": {
            "section_title": "infections caused by these bacteria has not been established in adequate and well-controlled clinical trials."
        }
    },
    {
        "page_number": 14,
        "section_number": 40,
        "content": "Aerobic Gram-Positive Bacteria",
        "metadata": {
            "section_title": "Aerobic Gram-Positive Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 41,
        "content": "Streptococci (Groups C, F , G)",
        "metadata": {
            "section_title": "Streptococci (Groups C, F , G)"
        }
    },
    {
        "page_number": 14,
        "section_number": 42,
        "content": "Viridans  group streptococci",
        "metadata": {
            "section_title": "Viridans  group streptococci"
        }
    },
    {
        "page_number": 14,
        "section_number": 43,
        "content": "Gram-Negative Bacteria",
        "metadata": {
            "section_title": "Gram-Negative Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 44,
        "content": "Bordetella pertussis",
        "metadata": {
            "section_title": "Bordetella pertussis"
        }
    },
    {
        "page_number": 14,
        "section_number": 45,
        "content": "Anaer obic Bacteria",
        "metadata": {
            "section_title": "Anaer obic Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 46,
        "content": "Peptostr eptococcus species",
        "metadata": {
            "section_title": "Peptostr eptococcus species"
        }
    },
    {
        "page_number": 14,
        "section_number": 47,
        "content": "Prevotella bivia",
        "metadata": {
            "section_title": "Prevotella bivia"
        }
    },
    {
        "page_number": 14,
        "section_number": 48,
        "content": "Other  Bacteria",
        "metadata": {
            "section_title": "Other  Bacteria"
        }
    },
    {
        "page_number": 14,
        "section_number": 49,
        "content": "Ureaplasma ur ealyticum",
        "metadata": {
            "section_title": "Ureaplasma ur ealyticum"
        }
    },
    {
        "page_number": 14,
        "section_number": 50,
        "content": "Susceptibility T esting",
        "metadata": {
            "section_title": "Susceptibility T esting"
        }
    },
    {
        "page_number": 14,
        "section_number": 51,
        "content": "For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control",
        "metadata": {
            "section_title": "For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control"
        }
    },
    {
        "page_number": 14,
        "section_number": 52,
        "content": "standards recognized by FDA  for this drug, please see: https://www .fda.gov/STIC.- 90% Confidence interval not reported",
        "metadata": {
            "section_title": "standards recognized by FDA  for this drug, please see: https://www .fda.gov/STIC.- 90% Confidence interval not reported"
        }
    },
    {
        "page_number": 14,
        "section_number": 53,
        "content": "B",
        "metadata": {
            "section_title": "B"
        }
    },
    {
        "page_number": 15,
        "section_number": 1,
        "content": "13 NONCLINICAL  TOXICOLOGY",
        "metadata": {
            "section_title": "13 NONCLINICAL  TOXICOLOGY"
        }
    },
    {
        "page_number": 15,
        "section_number": 2,
        "content": "13.1 Car cinogenesis, Mutagenesis, Impairment of Fertility",
        "metadata": {
            "section_title": "13.1 Car cinogenesis, Mutagenesis, Impairment of Fertility"
        }
    },
    {
        "page_number": 15,
        "section_number": 3,
        "content": "Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no",
        "metadata": {
            "section_title": "Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no"
        }
    },
    {
        "page_number": 15,
        "section_number": 4,
        "content": "mutagenic potential in standard laboratory tests: mouse lymphoma assay , human lymphocyte clastogenic assay , and mouse",
        "metadata": {
            "section_title": "mutagenic potential in standard laboratory tests: mouse lymphoma assay , human lymphocyte clastogenic assay , and mouse"
        }
    },
    {
        "page_number": 15,
        "section_number": 5,
        "content": "bone marrow clastogenic assay . In fertility studies conducted in male and female rats, oral administration of azithromycin for",
        "metadata": {
            "section_title": "bone marrow clastogenic assay . In fertility studies conducted in male and female rats, oral administration of azithromycin for"
        }
    },
    {
        "page_number": 15,
        "section_number": 6,
        "content": "64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 and 30",
        "metadata": {
            "section_title": "64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 and 30"
        }
    },
    {
        "page_number": 15,
        "section_number": 7,
        "content": "mg/kg/day when both males and females were treated with azithromycin. This minimal ef fect on pregnancy rate",
        "metadata": {
            "section_title": "mg/kg/day when both males and females were treated with azithromycin. This minimal ef fect on pregnancy rate"
        }
    },
    {
        "page_number": 15,
        "section_number": 8,
        "content": "(approximately 12% reduction compared to concurrent controls) did not become more pronounced when the dose was",
        "metadata": {
            "section_title": "(approximately 12% reduction compared to concurrent controls) did not become more pronounced when the dose was"
        }
    },
    {
        "page_number": 15,
        "section_number": 9,
        "content": "increased from 20 to 30 mg/kg/day (approximately 0.4 to 0.6 times the adult daily dose of 500 mg based on body surface area)",
        "metadata": {
            "section_title": "increased from 20 to 30 mg/kg/day (approximately 0.4 to 0.6 times the adult daily dose of 500 mg based on body surface area)"
        }
    },
    {
        "page_number": 15,
        "section_number": 10,
        "content": "and it was not observed when only one animal in the mated pair was treated. There were no ef fects on any other reproductive",
        "metadata": {
            "section_title": "and it was not observed when only one animal in the mated pair was treated. There were no ef fects on any other reproductive"
        }
    },
    {
        "page_number": 15,
        "section_number": 11,
        "content": "parameters, and there were no ef fects on fertility at 10 mg/kg/day . The relevance of these findings to patients being treated with",
        "metadata": {
            "section_title": "parameters, and there were no ef fects on fertility at 10 mg/kg/day . The relevance of these findings to patients being treated with"
        }
    },
    {
        "page_number": 15,
        "section_number": 12,
        "content": "azithromycin at the doses and durations recommended in the prescribing information is uncertain.",
        "metadata": {
            "section_title": "azithromycin at the doses and durations recommended in the prescribing information is uncertain."
        }
    },
    {
        "page_number": 15,
        "section_number": 13,
        "content": "13.2 Animal Toxicology and/or  Pharmacology",
        "metadata": {
            "section_title": "13.2 Animal Toxicology and/or  Pharmacology"
        }
    },
    {
        "page_number": 15,
        "section_number": 14,
        "content": "Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given",
        "metadata": {
            "section_title": "Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given"
        }
    },
    {
        "page_number": 15,
        "section_number": 15,
        "content": "multiple oral doses of azithromycin. It has been demonstrated in numerous or gan systems (e.g., eye, dorsal root ganglia, liver ,",
        "metadata": {
            "section_title": "multiple oral doses of azithromycin. It has been demonstrated in numerous or gan systems (e.g., eye, dorsal root ganglia, liver ,"
        }
    },
    {
        "page_number": 15,
        "section_number": 16,
        "content": "gallbladder , kidney , spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis",
        "metadata": {
            "section_title": "gallbladder , kidney , spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis"
        }
    },
    {
        "page_number": 15,
        "section_number": 17,
        "content": "of body surface area, are similar to or less than the highest recommended adult human dose. This ef fect has been shown to be",
        "metadata": {
            "section_title": "of body surface area, are similar to or less than the highest recommended adult human dose. This ef fect has been shown to be"
        }
    },
    {
        "page_number": 15,
        "section_number": 18,
        "content": "reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the",
        "metadata": {
            "section_title": "reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the"
        }
    },
    {
        "page_number": 15,
        "section_number": 19,
        "content": "rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL  (1.6 times the observed C  of 0.821",
        "metadata": {
            "section_title": "rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL  (1.6 times the observed C  of 0.821"
        }
    },
    {
        "page_number": 15,
        "section_number": 20,
        "content": "mcg/mL  at the adult dose of 2 g.) Similarly , it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum",
        "metadata": {
            "section_title": "mcg/mL  at the adult dose of 2 g.) Similarly , it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum"
        }
    },
    {
        "page_number": 15,
        "section_number": 21,
        "content": "concentration of 1 mcg/mL  (1.2 times the observed C  of 0.821 mcg/mL  at the adult dose of 2 g).",
        "metadata": {
            "section_title": "concentration of 1 mcg/mL  (1.2 times the observed C  of 0.821 mcg/mL  at the adult dose of 2 g)."
        }
    },
    {
        "page_number": 15,
        "section_number": 22,
        "content": "Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day , which is less than the pediatric dose of",
        "metadata": {
            "section_title": "Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day , which is less than the pediatric dose of"
        }
    },
    {
        "page_number": 15,
        "section_number": 23,
        "content": "60 mg/kg based on body surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean",
        "metadata": {
            "section_title": "60 mg/kg based on body surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean"
        }
    },
    {
        "page_number": 15,
        "section_number": 24,
        "content": "maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C  of 1.27 mcg/mL  at the pediatric dose.",
        "metadata": {
            "section_title": "maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C  of 1.27 mcg/mL  at the pediatric dose."
        }
    },
    {
        "page_number": 15,
        "section_number": 25,
        "content": "Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54",
        "metadata": {
            "section_title": "Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54"
        }
    },
    {
        "page_number": 15,
        "section_number": 26,
        "content": "mcg/mL, approximately 3 times the pediatric dose C . The significance of the findings for animals and for humans is",
        "metadata": {
            "section_title": "mcg/mL, approximately 3 times the pediatric dose C . The significance of the findings for animals and for humans is"
        }
    },
    {
        "page_number": 15,
        "section_number": 27,
        "content": "unknown.",
        "metadata": {
            "section_title": "unknown."
        }
    },
    {
        "page_number": 15,
        "section_number": 28,
        "content": "14 CLINICAL  STUDIES",
        "metadata": {
            "section_title": "14 CLINICAL  STUDIES"
        }
    },
    {
        "page_number": 15,
        "section_number": 29,
        "content": "14.1 Community-Acquir ed Pneumonia",
        "metadata": {
            "section_title": "14.1 Community-Acquir ed Pneumonia"
        }
    },
    {
        "page_number": 15,
        "section_number": 30,
        "content": "In a controlled trial of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by",
        "metadata": {
            "section_title": "In a controlled trial of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by"
        }
    },
    {
        "page_number": 15,
        "section_number": 31,
        "content": "the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was",
        "metadata": {
            "section_title": "the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was"
        }
    },
    {
        "page_number": 15,
        "section_number": 32,
        "content": "compared to cefuroxime (2,250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1,000",
        "metadata": {
            "section_title": "compared to cefuroxime (2,250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1,000"
        }
    },
    {
        "page_number": 15,
        "section_number": 33,
        "content": "mg/day in two divided doses by the oral route to complete 7 to 10 days therapy), with or without erythromycin. For the 291",
        "metadata": {
            "section_title": "mg/day in two divided doses by the oral route to complete 7 to 10 days therapy), with or without erythromycin. For the 291"
        }
    },
    {
        "page_number": 15,
        "section_number": 34,
        "content": "patients who were evaluable for clinical ef ficacy , the clinical outcome rates, i.e., cure, improved, and success (cure +",
        "metadata": {
            "section_title": "patients who were evaluable for clinical ef ficacy , the clinical outcome rates, i.e., cure, improved, and success (cure +"
        }
    },
    {
        "page_number": 15,
        "section_number": 35,
        "content": "improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:",
        "metadata": {
            "section_title": "improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:"
        }
    },
    {
        "page_number": 15,
        "section_number": 36,
        "content": "Clinical Outcome Azithr omycin Comparator",
        "metadata": {
            "section_title": "Clinical Outcome Azithr omycin Comparator"
        }
    },
    {
        "page_number": 15,
        "section_number": 37,
        "content": "Cure 46% 44%",
        "metadata": {
            "section_title": "Cure 46% 44%"
        }
    },
    {
        "page_number": 15,
        "section_number": 38,
        "content": "Improved 32% 30%",
        "metadata": {
            "section_title": "Improved 32% 30%"
        }
    },
    {
        "page_number": 15,
        "section_number": 39,
        "content": "Success (Cure + Improved) 78% 74%",
        "metadata": {
            "section_title": "Success (Cure + Improved) 78% 74%"
        }
    },
    {
        "page_number": 15,
        "section_number": 40,
        "content": "In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired",
        "metadata": {
            "section_title": "In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired"
        }
    },
    {
        "page_number": 15,
        "section_number": 41,
        "content": "pneumonia who received azithromycin in the same regimen were evaluable for clinical ef ficacy . The clinical outcome rates,",
        "metadata": {
            "section_title": "pneumonia who received azithromycin in the same regimen were evaluable for clinical ef ficacy . The clinical outcome rates,"
        }
    },
    {
        "page_number": 15,
        "section_number": 42,
        "content": "i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:",
        "metadata": {
            "section_title": "i.e., cure, improved, and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:"
        }
    },
    {
        "page_number": 15,
        "section_number": 43,
        "content": "Clinical Outcome Azithr omycin",
        "metadata": {
            "section_title": "Clinical Outcome Azithr omycin"
        }
    },
    {
        "page_number": 15,
        "section_number": 44,
        "content": "Cure 60%",
        "metadata": {
            "section_title": "Cure 60%"
        }
    },
    {
        "page_number": 15,
        "section_number": 45,
        "content": "Improved 29%",
        "metadata": {
            "section_title": "Improved 29%"
        }
    },
    {
        "page_number": 15,
        "section_number": 46,
        "content": "Success (Cure + Improved) 89%max",
        "metadata": {
            "section_title": "Success (Cure + Improved) 89%max"
        }
    },
    {
        "page_number": 15,
        "section_number": 47,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 15,
        "section_number": 48,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 15,
        "section_number": 49,
        "content": "max",
        "metadata": {
            "section_title": "max"
        }
    },
    {
        "page_number": 16,
        "section_number": 1,
        "content": "Hospira, Inc.Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at",
        "metadata": {
            "section_title": "Hospira, Inc.Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at"
        }
    },
    {
        "page_number": 16,
        "section_number": 2,
        "content": "later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive",
        "metadata": {
            "section_title": "later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive"
        }
    },
    {
        "page_number": 16,
        "section_number": 3,
        "content": "bacteriological eradication rates were obtained from the evaluable groups:",
        "metadata": {
            "section_title": "bacteriological eradication rates were obtained from the evaluable groups:"
        }
    },
    {
        "page_number": 16,
        "section_number": 4,
        "content": "Combined Bacteriological Eradication Rates for Azithromycin:",
        "metadata": {
            "section_title": "Combined Bacteriological Eradication Rates for Azithromycin:"
        }
    },
    {
        "page_number": 16,
        "section_number": 5,
        "content": "(at last completed visit) Azithr omycin",
        "metadata": {
            "section_title": "(at last completed visit) Azithr omycin"
        }
    },
    {
        "page_number": 16,
        "section_number": 6,
        "content": "S. pneumoniae 64/67 (96%)",
        "metadata": {
            "section_title": "S. pneumoniae 64/67 (96%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 7,
        "content": "H. influenzae 41/43 (95%)",
        "metadata": {
            "section_title": "H. influenzae 41/43 (95%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 8,
        "content": "M. catarr halis 9/10 (90%)",
        "metadata": {
            "section_title": "M. catarr halis 9/10 (90%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 9,
        "content": "S. aur eus 9/10 (90%)",
        "metadata": {
            "section_title": "S. aur eus 9/10 (90%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 10,
        "content": "Nineteen of twenty-four patients (79%) with positive blood cultures for S. pneumoniae were cured (intent-to-treat analysis)",
        "metadata": {
            "section_title": "   Nineteen of twenty-four patients (79%) with positive blood cultures for S. pneumoniae were cured (intent-to-treat analysis)"
        }
    },
    {
        "page_number": 16,
        "section_number": 11,
        "content": "with eradication of the pathogen.",
        "metadata": {
            "section_title": "with eradication of the pathogen."
        }
    },
    {
        "page_number": 16,
        "section_number": 12,
        "content": "The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence",
        "metadata": {
            "section_title": "The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence"
        }
    },
    {
        "page_number": 16,
        "section_number": 13,
        "content": "(serology and/or culture) of atypical pathogens for both trials were as follows:",
        "metadata": {
            "section_title": "(serology and/or culture) of atypical pathogens for both trials were as follows:"
        }
    },
    {
        "page_number": 16,
        "section_number": 14,
        "content": "Evidence of Infection Total Cure Impr oved Cure + Impr oved",
        "metadata": {
            "section_title": "Evidence of Infection Total Cure Impr oved Cure + Impr oved"
        }
    },
    {
        "page_number": 16,
        "section_number": 15,
        "content": "Mycoplasma pneumoniae 18 11 (61%) 5 (28%) 16 (89%)",
        "metadata": {
            "section_title": "Mycoplasma pneumoniae 18 11 (61%) 5 (28%) 16 (89%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 16,
        "content": "Chlamydia pneumoniae 34 15 (44%) 13 (38%) 28 (82%)",
        "metadata": {
            "section_title": "Chlamydia pneumoniae 34 15 (44%) 13 (38%) 28 (82%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 17,
        "content": "Legionella pneumophila 16 5 (31%) 8 (50%) 13 (81%)",
        "metadata": {
            "section_title": "Legionella pneumophila 16 5 (31%) 8 (50%) 13 (81%)"
        }
    },
    {
        "page_number": 16,
        "section_number": 18,
        "content": "16 HOW  SUPPLIED/ST ORAGE AND HANDLING",
        "metadata": {
            "section_title": "16 HOW  SUPPLIED/ST ORAGE AND HANDLING"
        }
    },
    {
        "page_number": 16,
        "section_number": 19,
        "content": "Azithromycin for Injection, USP  is supplied as white to of f-white lyophilized powder under a vacuum in a single-dose vial",
        "metadata": {
            "section_title": "Azithromycin for Injection, USP  is supplied as white to of f-white lyophilized powder under a vacuum in a single-dose vial"
        }
    },
    {
        "page_number": 16,
        "section_number": 20,
        "content": "equivalent to 500 mg of azithromycin for intravenous administration.",
        "metadata": {
            "section_title": "equivalent to 500 mg of azithromycin for intravenous administration."
        }
    },
    {
        "page_number": 16,
        "section_number": 21,
        "content": "These are packaged as follows:",
        "metadata": {
            "section_title": "These are packaged as follows:"
        }
    },
    {
        "page_number": 16,
        "section_number": 22,
        "content": "Unit of Sale Concentration",
        "metadata": {
            "section_title": "Unit of Sale Concentration"
        }
    },
    {
        "page_number": 16,
        "section_number": 23,
        "content": "NDC 0409-0144-10 500 mg/vial",
        "metadata": {
            "section_title": "NDC 0409-0144-10 500 mg/vial"
        }
    },
    {
        "page_number": 16,
        "section_number": 24,
        "content": "Tray containing 10 single-dose vials",
        "metadata": {
            "section_title": "Tray containing 10 single-dose vials"
        }
    },
    {
        "page_number": 16,
        "section_number": 25,
        "content": "Store at 20 to 25ºC (68 to 77ºF). [See USP  Controlled Room Temperature.]",
        "metadata": {
            "section_title": "Store at 20 to 25ºC (68 to 77ºF). [See USP  Controlled Room Temperature.]"
        }
    },
    {
        "page_number": 16,
        "section_number": 26,
        "content": "17 PATIENT  COUNSELING INFORMA TION",
        "metadata": {
            "section_title": "17 PATIENT  COUNSELING INFORMA TION"
        }
    },
    {
        "page_number": 16,
        "section_number": 27,
        "content": "Patients should be informed of the following serious and potentially serious adverse reactions that have been associated with",
        "metadata": {
            "section_title": "Patients should be informed of the following serious and potentially serious adverse reactions that have been associated with"
        }
    },
    {
        "page_number": 16,
        "section_number": 28,
        "content": "Azithromycin for Injection:",
        "metadata": {
            "section_title": "Azithromycin for Injection:"
        }
    },
    {
        "page_number": 16,
        "section_number": 29,
        "content": "Diarrhea: Inform patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the",
        "metadata": {
            "section_title": "Diarrhea: Inform patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the"
        }
    },
    {
        "page_number": 16,
        "section_number": 30,
        "content": "antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody",
        "metadata": {
            "section_title": "antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody"
        }
    },
    {
        "page_number": 16,
        "section_number": 31,
        "content": "stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the",
        "metadata": {
            "section_title": "stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the"
        }
    },
    {
        "page_number": 16,
        "section_number": 32,
        "content": "antibacterial. If this occurs, patients should notify their physician as soon as possible.",
        "metadata": {
            "section_title": "antibacterial. If this occurs, patients should notify their physician as soon as possible."
        }
    },
    {
        "page_number": 16,
        "section_number": 33,
        "content": "Distributed by Hospira, Inc., Lake Forest, IL  60045 USA",
        "metadata": {
            "section_title": "Distributed by Hospira, Inc., Lake Forest, IL  60045 USA                                                                                       "
        }
    },
    {
        "page_number": 16,
        "section_number": 34,
        "content": "LAB-101 1-7.0",
        "metadata": {
            "section_title": "LAB-101 1-7.0"
        }
    },
    {
        "page_number": 16,
        "section_number": 35,
        "content": "aa",
        "metadata": {
            "section_title": " aa"
        }
    },
    {
        "page_number": 16,
        "section_number": 36,
        "content": "Revised: 2/2022",
        "metadata": {
            "section_title": "Revised: 2/2022"
        }
    }
]